US20120058327A1 - Robust Hybrid Thin Films that Incorporate Lamellar Phospholipid Bilayer Assemblies and Transmembrane Proteins - Google Patents
Robust Hybrid Thin Films that Incorporate Lamellar Phospholipid Bilayer Assemblies and Transmembrane Proteins Download PDFInfo
- Publication number
- US20120058327A1 US20120058327A1 US13/232,647 US201113232647A US2012058327A1 US 20120058327 A1 US20120058327 A1 US 20120058327A1 US 201113232647 A US201113232647 A US 201113232647A US 2012058327 A1 US2012058327 A1 US 2012058327A1
- Authority
- US
- United States
- Prior art keywords
- lipid
- polymer
- polymer membrane
- membrane
- hybrid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000010409 thin film Substances 0.000 title abstract description 34
- 238000000429 assembly Methods 0.000 title abstract description 30
- 230000000712 assembly Effects 0.000 title abstract description 30
- 150000003904 phospholipids Chemical class 0.000 title abstract description 25
- 102000035160 transmembrane proteins Human genes 0.000 title abstract description 10
- 108091005703 transmembrane proteins Proteins 0.000 title abstract description 10
- 150000002632 lipids Chemical class 0.000 claims abstract description 77
- 239000012528 membrane Substances 0.000 claims abstract description 32
- -1 biological complexes Proteins 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 58
- 239000000377 silicon dioxide Substances 0.000 claims description 46
- 230000001154 acute effect Effects 0.000 claims description 36
- 229910052710 silicon Inorganic materials 0.000 claims description 27
- 239000010703 silicon Substances 0.000 claims description 27
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 25
- 229920000642 polymer Polymers 0.000 claims description 18
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 8
- 102000004310 Ion Channels Human genes 0.000 claims description 6
- 108090000862 Ion Channels Proteins 0.000 claims description 6
- 230000009056 active transport Effects 0.000 claims description 6
- VXUOFDJKYGDUJI-OAQYLSRUSA-N 1-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C VXUOFDJKYGDUJI-OAQYLSRUSA-N 0.000 claims description 5
- 108091006146 Channels Proteins 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 5
- 229920000620 organic polymer Polymers 0.000 claims description 5
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 4
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 claims description 4
- XDLMVUHYZWKMMD-UHFFFAOYSA-N 3-trimethoxysilylpropyl 2-methylprop-2-enoate Chemical compound CO[Si](OC)(OC)CCCOC(=O)C(C)=C XDLMVUHYZWKMMD-UHFFFAOYSA-N 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 239000010931 gold Substances 0.000 claims description 4
- 229910052737 gold Inorganic materials 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 claims description 4
- NEZDNQCXEZDCBI-WJOKGBTCSA-N (2-aminoethoxy)[(2r)-2,3-bis(tetradecanoyloxy)propoxy]phosphinic acid Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-WJOKGBTCSA-N 0.000 claims description 3
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 claims description 3
- YYJKEIKJPLRCEQ-MZMPXXGTSA-N [(2r)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroperoxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OO)COP(O)(=O)OCCN YYJKEIKJPLRCEQ-MZMPXXGTSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- LFQCEHFDDXELDD-UHFFFAOYSA-N tetramethyl orthosilicate Chemical compound CO[Si](OC)(OC)OC LFQCEHFDDXELDD-UHFFFAOYSA-N 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- HPEPIADELDNCED-UHFFFAOYSA-N triethoxysilylmethanol Chemical compound CCO[Si](CO)(OCC)OCC HPEPIADELDNCED-UHFFFAOYSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 229920000936 Agarose Polymers 0.000 claims description 2
- 101710092462 Alpha-hemolysin Proteins 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 claims description 2
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 108010013381 Porins Proteins 0.000 claims description 2
- 102000017033 Porins Human genes 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 2
- 229920000592 inorganic polymer Polymers 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- MNCGMVDMOKPCSQ-UHFFFAOYSA-M sodium;2-phenylethenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C=CC1=CC=CC=C1 MNCGMVDMOKPCSQ-UHFFFAOYSA-M 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229920005597 polymer membrane Polymers 0.000 claims 17
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 27
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 5
- 239000002551 biofuel Substances 0.000 abstract description 4
- 230000011712 cell development Effects 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 4
- 230000018109 developmental process Effects 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 230000007613 environmental effect Effects 0.000 abstract description 4
- 238000012544 monitoring process Methods 0.000 abstract description 4
- 230000009919 sequestration Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 229920001184 polypeptide Polymers 0.000 abstract description 3
- 238000002441 X-ray diffraction Methods 0.000 description 37
- 239000000203 mixture Substances 0.000 description 33
- 239000010408 film Substances 0.000 description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 238000000527 sonication Methods 0.000 description 24
- 235000012431 wafers Nutrition 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 16
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 16
- 238000004627 transmission electron microscopy Methods 0.000 description 16
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- 108010026389 Gramicidin Proteins 0.000 description 11
- 229960004905 gramicidin Drugs 0.000 description 11
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 11
- 238000012856 packing Methods 0.000 description 11
- 229910001868 water Inorganic materials 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000002243 precursor Substances 0.000 description 10
- 241000252506 Characiformes Species 0.000 description 8
- 239000002086 nanomaterial Substances 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 108010082845 Bacteriorhodopsins Proteins 0.000 description 6
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 6
- 238000005520 cutting process Methods 0.000 description 6
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 238000006748 scratching Methods 0.000 description 6
- 230000002393 scratching effect Effects 0.000 description 6
- 238000003260 vortexing Methods 0.000 description 6
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 5
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003012 bilayer membrane Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000004330 Rhodopsin Human genes 0.000 description 3
- 108090000820 Rhodopsin Proteins 0.000 description 3
- 238000003917 TEM image Methods 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 210000004676 purple membrane Anatomy 0.000 description 3
- FGGPAWQCCGEWTJ-UHFFFAOYSA-M sodium;2,3-bis(sulfanyl)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(S)CS FGGPAWQCCGEWTJ-UHFFFAOYSA-M 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- PYVRVRFVLRNJLY-MZMPXXGTSA-N 1-oleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OCCN PYVRVRFVLRNJLY-MZMPXXGTSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- 102000003939 Membrane transport proteins Human genes 0.000 description 2
- 108090000301 Membrane transport proteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 2
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 238000001354 calcination Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229930003827 cannabinoid Natural products 0.000 description 2
- 239000003557 cannabinoid Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- FFQQCJGNKKIRMD-UHFFFAOYSA-N methyl n-(3-hydroxyphenyl)carbamate Chemical compound COC(=O)NC1=CC=CC(O)=C1 FFQQCJGNKKIRMD-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000009057 passive transport Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940127293 prostanoid Drugs 0.000 description 2
- 150000003814 prostanoids Chemical class 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000000580 secretagogue effect Effects 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 238000004528 spin coating Methods 0.000 description 2
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- HWYCFZUSOBOBIN-AQJXLSMYSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-n-[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-5-(diaminome Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=CC=C1 HWYCFZUSOBOBIN-AQJXLSMYSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- TUCVPZNBGBRVRL-UHFFFAOYSA-N 9'-chloro-3',10'-dihydroxyspiro[2-benzofuran-3,7'-benzo[c]xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=CC2=CC(O)=CC=C21 TUCVPZNBGBRVRL-UHFFFAOYSA-N 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 102100026439 Adhesion G protein-coupled receptor E1 Human genes 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 102400001318 Adrenomedullin Human genes 0.000 description 1
- 101800004616 Adrenomedullin Proteins 0.000 description 1
- 108010089414 Anaphylatoxins Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 101710158332 Diuretic hormone Proteins 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102100021243 G-protein coupled receptor 182 Human genes 0.000 description 1
- 101710101415 G-protein coupled receptor 182 Proteins 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 102400001370 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000011714 Glycine Receptors Human genes 0.000 description 1
- 108010076533 Glycine Receptors Proteins 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 101000718225 Homo sapiens Adhesion G protein-coupled receptor E1 Proteins 0.000 description 1
- 101001009547 Homo sapiens Prosaposin receptor GPR37 Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 102400001355 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- 102100038813 Neuromedin-U Human genes 0.000 description 1
- 102400001095 Neuropeptide FF Human genes 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 1
- 229920002415 Pluronic P-123 Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102100030284 Prosaposin receptor GPR37 Human genes 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010067973 Valinomycin Proteins 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- FCFNRCROJUBPLU-UHFFFAOYSA-N compound M126 Natural products CC(C)C1NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC1=O FCFNRCROJUBPLU-UHFFFAOYSA-N 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002188 infrared transmission spectroscopy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002535 lyotropic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 108010021512 neuromedin U Proteins 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 108010003516 norsynephrine receptor Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 108010055752 phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide Proteins 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 238000001355 polarised Fourier transform infrared spectroscopy Methods 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001004 secondary ion mass spectrometry Methods 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 239000013545 self-assembled monolayer Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- QLNOOKSBAYIHQI-SKZICHJRSA-M sodium;2,3-dihydroxypropyl [(2r)-2,3-di(tetradecanoyloxy)propyl] phosphate Chemical compound [Na+].CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC QLNOOKSBAYIHQI-SKZICHJRSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000003980 solgel method Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- FCFNRCROJUBPLU-DNDCDFAISA-N valinomycin Chemical compound CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O FCFNRCROJUBPLU-DNDCDFAISA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/249921—Web or sheet containing structurally defined element or component
- Y10T428/249953—Composite having voids in a component [e.g., porous, cellular, etc.]
- Y10T428/249967—Inorganic matrix in void-containing component
- Y10T428/24997—Of metal-containing material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/249921—Web or sheet containing structurally defined element or component
- Y10T428/249953—Composite having voids in a component [e.g., porous, cellular, etc.]
- Y10T428/249978—Voids specified as micro
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/249921—Web or sheet containing structurally defined element or component
- Y10T428/249953—Composite having voids in a component [e.g., porous, cellular, etc.]
- Y10T428/249987—With nonvoid component of specified composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
- Y10T428/31652—Of asbestos
- Y10T428/31663—As siloxane, silicone or silane
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
- Y10T428/31678—Of metal
Definitions
- the present invention relates to hybrid thin films. More specifically the present invention relates to methods for incorporating polypeptides, biological complexes, transmembrane proteins and other membrane-associated components into hybrid thin films and methods of using the same.
- Phospholipids are a major component of all biological membranes.
- a phospholipid is composed of glycerol bonded to two fatty acids and a phosphate group. Due to its polar nature, the head of a phospholipid is hydrophilic while the nonpolar tails are hydrophobic.
- phospholipids When placed in water, phospholipids form a bilayer, composed of a hydrophobic core region formed by the acyl chains of the lipids, and hydrophilic membrane interfacial regions that are formed by the polar head groups of the lipids.
- Membranes made of phospholipid bilayers are partially permeable, very flexible, and have fluid properties in which embedded proteins and phospholipid molecules are constantly moving laterally across the membrane. Proteins incorporated into the phospholipid bilayer can facilitate actions such as compartmentalization, passive and active transport, signal transduction, specific recognition, and energy utilization.
- phospholipid bilayer membranes Because of their versatility in function, scientists have long sought to incorporate phospholipid bilayer membranes into artificial materials and devices. These devices have a broad range of potential applications including ligand based biosensors for clinical diagnostics; memory devices; screening devices for pharmaceutical applications; the provision of biologically functionalized surfaces; binding sites for small molecules such as drugs, pesticides, molecules required to be analyzed during process control (i.e. food stuffs, fermenter products, chemicals); larger molecules such as proteins for research screening (e.g.
- diagnostics cancer markers, infectious disease markers, hormones
- nucleic acids carbohydrate polymers
- cells such as pathogenic bacteria
- eukaryotic cells such as cancer cells and small single or multicellular organisms especially parasites
- high throughput screening for pharmaceutical applications controlled drug delivery; medical diagnosis; environmental monitoring, chemical and biological warfare agent sequestration; actuator development; power sources; electrochemical pumps; and bio-fuel cell development.
- phospholipid bilayer membranes are inherently fragile. Due to their thinness, polar charge, tendency to naturally curve, and the inherently weak self-assembly forces at work, they are subject to disruption from phenomenon such as vibration, sonication, chemical reaction, pH, temperature denaturing, electromagnetic fields and the like making them unsuitable for applications outside of the most stringently controlled conditions. Additionally, it has been difficult to create membranes with uniform nanostructures capable of incorporating other proteins such as transmembrane proteins in nonrandom orientations.
- FIGS. 1A and B show TEM micrographs of the surface and the x-ray diffraction pattern (inset) of a lipid-silica thin film (2.5 wt % lipid in stock sol) made with (A) 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and (B) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC).
- DMPC 1,2-dimyristoyl-sn-glycero-3-phosphocholine
- DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine
- FIG. 2 is the x-ray diffraction pattern of 2.5% wt lipid-water-ethanol coated film on silicon wafer made using DMPC.
- FIG. 3 shows the x-ray diffraction pattern of lipid EggPC-silica thin film (2.5 wt % lipid in stock sol) (A) before the addition of cholesterol and (B) after the addition of cholesterol (4:1 EggPC:cholesterol).
- FIGS. 4 A and B are x-ray diffraction patterns of 2.5 wt % lipid-silica assemblies made using (A) saturated or (B) unsaturated lipids.
- FIG. 5 shows the x-ray diffraction pattern of 2.5 wt % lipid-silica assemblies made using a 1:1 combination of EggPC and DOPE before sonication and after sonication.
- FIGS. 6A and B are micrographs of the surface of DOPE-silica thin films prepared with (A) 10 wt % DOPE in stock sol and (B) lwt % DOPE.
- FIG. 6C is the X is the x-ray diffraction pattern of DOPE-silica films prepared from 10, 5.0, 2.5, 1 and 0.1 wt % DOPE.
- FIGS. 7A and B are images of the results of vesicle entrapment in lipid-silica assemblies made using EggPC taken using (A) TEM and (B) x-ray diffraction.
- FIGS. 8 A and B are TEM micrographs of DOPE-silica thin films prepared from 2.5 wt % DOPE and bacteriorhodopsin in a 100:1 DOPE:bR ratio (A) without sonication and (B) with sonication.
- FIG. 8 C is an x-ray diffraction pattern of DOPE-silica thin films prepared from 2.5 wt % DOPE and bacteriorhodopsin in a 100:1 DOPE:bR ratio with and without sonication.
- FIG. 9 shows the x-ray diffraction patterns of DOPE-silica thin films (A) with sonication, (B) without sonication, (C) with gramicidin but without sonication and (D) with gramicidin and sonication.
- FIG. 9B is the transmission IR spectrum of gramicidin-DOPE-silica assemblies prepared with a 10:1 lipid:peptide ratio.
- FIG. 10 is the x-ray diffraction pattern for lipid-silica matrices demonstrating that the positions of the diffraction peaks were in integer multiples indicating the lamellar nature of CTAB in the silica matrix.
- the present invention provides methods for preparing hybrid bioorganic-inorganic thin films with specific architecture.
- Such thin films can be used in a variety of applications including, but not limited to, biosensors, medical diagnosis, environmental monitoring, chemical and biological warfare agent sequestration, actuator development, power sources, sensing platforms, electrochemical pumps, and bio-fuel cell development.
- the present invention further provides methods for preparing hybrid bioorganic-inorganic thin films that can exhibit selective and active transport function.
- the present invention additionally provides methods for preparing functional biosynthetic cell membrane components encapsulated in nanostructured membrane architectures.
- Phospholipid bilayer membranes are essential components of cellular systems. They enable a variety of functions including compartmentalization, passive and active transport, signal transduction, specific recognition and energy utilization. Formation of phospholipid bilayers is influenced by factors such as the surfactant used, pH, salt concentration, type of solvent and temperature at which the assemblies are synthesized.
- the thin films formed by the methods herein are artificial assemblies which self assemble with phospholipids and phospholipid mixtures into micellar and lyotrophic liquid crystalline phases.
- a lamellar structure may be constructed in which hydrophilic crosslinked polymer nanophases are separated by parallel lipid bilayers.
- the lamellae are parallel to the film surface.
- the lamellar assemblies are highly ordered.
- the thin films contain uniform nanostructures that are amenable to the incorporation of functional amphiphilic proteins, peptides and other biomolecular complexes in nonrandom orientations.
- the nanostructures created by the methods of the present invention may be planar or vesicle like.
- the structures exhibit uniform d-spacing of between 35 to 48 ⁇ acute over ( ⁇ ) ⁇ .
- the uniform d-spacing is 44 ⁇ acute over ( ⁇ ) ⁇ .
- the polymer and phospholipid bilayers may alternate.
- processing conditions may be altered to effect the orientation of the transmembrane protein or other biomolecular complex.
- the scale of these thin films may be from about 5 to about 500 nm, about 5 to about 100 nm or about 5 to about 50 nm in width.
- liposomes may be formed using lipid-polymer hybrid membranes. These liposomes may be about 40 nm to about 100 nm, and more preferably about 50 to about 100 nm.
- Thin films incorporating phospholipid bilayer assemblies may be constructed using saturated or unsaturated lipids with a packing fraction parameter of between 0.5 to 1.
- the thin films may contain highly ordered lyotrophic crystalline surfactant phases encapsulated in rigid silica matrices.
- the thin films of the present invention are generally formed using a precursor sol, solvent, acid, water and dried phospholipids.
- the precursor sol may be formed by combining a polymer or hydrogel, a solvent, and water.
- Exemplary polymers for use within the methods and compositions of the present invention include, but are not limited to, inorganic polymers such as tetramethylorthosilicate, tetraethylorthosilicate, aminopropyltrimethyoxysilane, hydroxymethyltriethoxysilane, methacryloxypropyl trimethoxysilane, and hydroxyethyl methacrylate; organic polymers including non-ionic organic polymers such as poly (vinyl alcohol), poly (vinyl pyrrolidone), poly (ethylene oxide), hydroxy-propyl cellulose, dextran, agarose, dissacharides: sucrose, glucose and trehalose; anionic organic polymers such as poly (acrylic acid), poly (sodium sty
- the polymer may be silica based.
- exemplary silicas include, but are not limited to, tetraalkoxysilanes such as tetraethylorthosilicate or tetramethyl-orthosilicate; trialkoxysilane such as aminopropyltrimethyoxysilane, hydroxymethyltriethoxysilane or methacryloxypropyl trimethoxysilane; or combinations thereof.
- Such polymers form a matrix, for example through a siloxane condensation reaction, whose nanostructure may be determined by the organized lipid structures.
- surfactant may be added to the precursor sol. Any surfactant which forms a lamellar structure in the polymer matrix may be used. The lamellar nature of the surfactant may be determined by any means applicable. In one embodiment the structure of a film constructed using a surfactant may be determined through x-ray diffraction as seen in FIG. 10 .
- FIG. 10 depicts the x-ray diffraction pattern for a highly ordered nano structured silica/surfactant membrane prepared using cetyltrimethyl ammonium bromide (CTAB), aminopropyltrimethoyoxysilane and the exemplary phospholipids listed below.
- CTAB cetyltrimethyl ammonium bromide
- the positions of the diffraction peaks in FIG. 10 are in integer multiples indicating the lamellar nature of CTAB in the silica matrix.
- Lipids for use within the methods and compositions of the present invention may include saturated or unsaturated lipids.
- the selection of particular lipids and the concentration of lipids may depend in part on the type of resulting thin film and nanostructures to be obtained.
- the lipids form 0.01-50% wt of the resulting solution.
- the lipids from between about 1 to 30% wt, preferably about 5 to 20% wt, more preferably about 5 to 10% wt, more preferably 0.01 to about 10% weight of the resulting solution.
- the concentration of the lipids may effect the d spacing of the lamellar structures.
- an increase in the concentration of the lipid may be used to increase the d spacing in the resulting nanostructures.
- the selection of a particular lipid may be based on a number of factors including, but not limited to, the packing coefficient, charge, the length of the tails, and the number of chains per headgroup.
- Potential structures may be predicted by determining the packing parameters of the lipids used to construct the membranes.
- Different packing parameters or shape factor g (v hc /a o l c ) of amphiphiles, where a o is the optimal head group area, l c is the critical length of the hydrocarbon chain, and v hc is the volume of hydrocarbon chains, may be used to predict or interpret the microstructure of lipid-polymer assemblies.
- Different parameters may generate lamellar, hexagonal or cubic structures. For example, a lamellar phase, such as that created by the methods of the present invention, is obtained when the packing fraction parameter is between 0.5 to 1.
- V hc 2 ⁇ [( n c ⁇ 2) ⁇ v CH2 +v CH3 ]
- the head group area for a PC molecule is estimated to be 62 ⁇ acute over ( ⁇ ) ⁇ 2 .
- the maximum extended chain length of the phospholipids is given by the relation
- the packing fraction parameter for the lipid DMPC is as follows:
- the head group area, a o is effectively increased by approximately 10% due to the positive charge on the DMPC molecule at pH 2.2, where the phosphate group is protonated.
- the net packing parameter of DMPC molecule with pH factor taken into account is therefore as follows:
- Packing parameters vary depending on whether saturated or unsaturated lipids are used.
- the contrast in the packing parameters of saturated and unsaturated lipids in the hybrid phospholipid-silica thin film assemblies of the present invention can be seen, for example, in a comparison of FIGS. 1A and 1B .
- d spacing observed for film created using DMPC is 42 to 44 ⁇ acute over ( ⁇ ) ⁇ .
- Four order of diffraction peaks are observed for saturated lipids with a peak ratio is 1:2:3:4.
- d spacing for a film created using DOPE is approximately 47 ⁇ acute over ( ⁇ ) ⁇ with a first order diffraction peak at 47 ⁇ acute over ( ⁇ ) ⁇ and a second order peak at 24 ⁇ .
- the length of the lipid chain also influences the end structure of the thin film. As demonstrated in the examples below, lipids with chain lengths of 14 carbon atoms yield a d-spacing of 42-44 ⁇ acute over ( ⁇ ) ⁇ whereas lipids with a chain length of 18 carbon atoms yield a d-spacing of 47-49 ⁇ . It was therefore determined that there was an increase in d-spacing of approximately 1.2 ⁇ acute over ( ⁇ ) ⁇ for each carbon added to the chain.
- the charge of the headgroup effects membrane formation.
- Lipids with a positively charged headgroup at pH 2.2 and lipids capable of hydrogen bonding yield lamellar-lipid silica assemblies of the present invention, whereas lipids with neutral or negatively charged headgroups failed to form the desired structures. While not wishing to be bound, it is currently theorized that the charge may influence the effective size of the head group of the lipid, thereby altering the packing parameter and hence the formation of the lipid assembly.
- Exemplary phospholipids for use within the invention include, but are not limited to, 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC; 14:0); 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE; 14:0); 1,2-dimyristoyl-sn-g/ycero-3-[phospho-rac-(1-glycerol)] (Sodium Salt)(DMPG, 14:0); 1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine (14:O Lyso PC); 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC; 18:1 (cis)); 1-oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (18:1 Lyso PE); 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE, 18:1); L-phosphatidylcho
- cholesterol may be added to mixtures containing unsaturated lipids.
- Cholesterol may be added to the dried lipid, the precursor sol, or a combined mixture of dried lipid and precursor sol in varying concentrations from about 0 to 50% weight of the lipid mixture, preferably about 10 to 40% weight, more preferably about 15 to 30% weight.
- the selected lipids are hydrated in the precursor sol to form a lipid-polymer solution.
- the resulting solution may be homogenized.
- Such a homogenized solution may be further treated, for example, through sonication or extrusion.
- Such solutions may then be used to form the hybrid thin films of the present invention.
- such thin films may further incorporate additional biomolecular complexes including transmembrane proteins which may be used in the transport of solutes.
- biomolecular complexes may be incorporated with specific orientations. The particular orientation of a biomolecular complex may be varied depending on the conditions used. Such variation may effect the flow of the analyte species transported by the biomolecular complex.
- the resulting synthetic and hybrid biosynthetic membranes of the present invention have unprecedented levels of specificity towards aqueous solutes.
- the membrane systems of the invention can include transmembrane proteins that are involved in active transport by proton, ion and molecular pumping mechanisms.
- Biomolecular complexes may be included in the membranes by combining the lipids with additional proteins or peptides prior to hydration. In other embodiments, such biomolecular complexes may be included by adding them directly to the precursor sol either before or after the addition of lipids.
- biomolecular complexes including proteins and peptides that may be incorporated into the hybrid thin films of the present invention include, but are not limited to, g protein coupled receptors including, but not limited to, Class A (Rhodopsin-like) G protein coupled receptors which bind amines, peptides, hormone proteins, rhodopsin, olfactory prostanoid, nucleotide-like compounds, cannabinoids, platelet activating factor, gonadotropin-releasing hormone, thyrotropin-releasing hormone and secretagogue, melatonin and lysosphingolipid and LPA; G protein coupled receptors with amine ligands including, but not limited to, acetylcholine or muscarinic, adrenoceptors, dopamine, histamine, serotonin or octopamine receptors; peptide ligands including, but not limited to, angiotensin, bombesin, bradykin
- the incorporated functioning protein may be bacteriorhodopsin.
- Bacteriorhodopsin (bR) is a 26 kDa transmembrane protein that uses a photochemical process to transport protons across the cell membrane against an electrochemical potential of up to 250 mV, translating to a 105 fold difference in proton concentration across the membrane. It is considered to be a prototype for a class of membrane transporters and also serves as a structural model for the G-protein-coupled receptors. (J.-P. Cartailler and H. Luecke, Annu. Rev. Biophys. Biomol. Struct. 326, 1317 (2003))
- the incorporated functioning protein may be gramicidin.
- Gramicidin is a model ion channel with alternating D and L amino acids. Gramicidin dimerizes to from a conductive state where two 15-amino acid peptides forming B-helices meet head to head at their N-termini in the interior of a lipid bilayer. The outer surface of the gramicidin that interacts with the lipids is hydrophobic in nature, and only monovalent cations pass through the more polar core of the helix. (A. Finkelstein and O. S. Andersen, J. Membr. Biol. 59, 155 (1981))
- the hydrated polymer-lipid or polymer-lipid-biomolecular complex solution may additionally be coated onto a solid support. Coating may occur using any method known to those with skill in the art.
- the solution is spin coated.
- the solution is dip coated.
- the solution may be deposited on a solid support using a combination of spin and dip coating.
- Solid supports may be macro or mesoporous. Exemplary solid supports include, but are not limited to, silicon wafer, silane-silicon, self assembled monolayer-gold, SnO 2 , polymer coated substrates, gold, gold-SAM, or porous Alumina.
- solid supports may be planar or non-planar and formed as wafers or chips with regular or irregular surfaces, beads, microstructures, etc.
- preferential evaporation of the solvent results in a concentration of lipids in a manner that allows their self-assembly into micellar and lyotropic liquid crystalline phases while a polymer matrix forms based on the organization of the lipid structures.
- the formation of uniform nanonstructures in the hybrid membranes of the present invention may be determined by any means applicable. In some embodiments, such determinations may be made using x-ray diffraction technology. Uniform nanostructures will generate regular d-spacings. In another embodiment, transmission electron microscopy may be used to determine the structure of the membranes. In a further embodiment, the orientation of functioning proteins may be examined by polarized Fourier transform infrared spectroscopy or secondary ion mass spectrometry.
- a host cell includes a plurality (for example, a culture or population) of such host cells, and so forth.
- Tetraethyl otrthosilicate (TEOS), ethanol, deionized water, and 0.07 N HCl were mixed in the molar ratio of 1.0 TEOS:3.8 C 2 H 5 OH: 1.0 H 2 O: 5 ⁇ 10 ⁇ 5 HCL and refluxed at 60° C. for 90 minutes.
- the resulting solution was diluted with 4 ml ethanol (1:2) followed by the addition of approximately 0.16 ml water and dilute 0.07 N HCl.
- lipids obtained from Avanti Polar Lipids (Alabaster, Ala.), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC; 14:0); 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE; 14:0); 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (Sodium Salt) (DMPG, 14:0); 1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine (14:0 Lyso PC); 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC; 18:1 (cis)); 1-oleoyl-2-hydroxy-sn-glycero-3
- the resulting films were characterized using X-ray diffraction and transmission electron microscopy.
- Transmission electron microscopy was performed using a JEOL 2010 (Tokyo, Japan) with 200 kv accelerating voltage equipped with a Gatan slow scan CCD camera (Pleasanton, Calif.). The samples were prepared either by scratching the films from silicon substrates using a cutting blade or by using standard cross-section techniques.
- the d spacing observed for the film created using DMPC is 42 to 44 ⁇ acute over ( ⁇ ) ⁇ .
- Four order of diffraction peaks are observed for saturated lipids and the peak ratio is 1:2:3:4 exhibiting lamellar structure. Additionally, the x-ray diffraction pattern is most consistent with a lamellar phase structure with alternating phospholipid and silica layers that are parallel to the film surface.
- the d-spacing obtained for the lipid-water system is 48 ⁇ acute over ( ⁇ ) ⁇ .
- the peaks are in a ratio of 1:2:3:4:5 demonstrating the lamellar structure of alternating lipid and water layers.
- Egg phosphatidylcholine is a mixture of phosphatidylcholines that differ in their fatty acid composition.
- the formulation used in this experiment was obtained from Avanti Polar Lipids (Alabaster, Ala.) and has a fatty acid distribution of 16:0 (34%), 16:1(2%), 18:0(11%), 18:1(32%), 18:2(18%), 20:4 (3%).
- Lipid silica assemblies were prepared using Egg PC alone, cholesterol alone and varying mixtures of Egg PC and cholesterol.
- the Egg PC was prepared by hydrating Egg PC with stock sol of Example I for 1 hour. From 5 mol % to 50 mol % of cholesterol were added to aliquots of the hydrated Egg PC.
- the resulting mixtures were then individually homogenized by vortexing for 5 minutes at room temperature and then subjected to sonication for 5 minutes at room temperature using a VWR bath sonicator (power rating-9) (VWR International, West Chester, Pa.) before being coated at a speed of 3000 RPM for one minute onto silicon wafers which had previously been cleaned with a piranha solution of a 3:1 mixture of sulfuric acid and 30% hydrogen peroxide.
- VWR bath sonicator power rating-9
- the resulting films were characterized using X-ray diffraction and transmission electron microscopy.
- Transmission electron microscopy was performed using a JEOL 2010 (Tokyo, Japan) with 200 kv accelerating voltage equipped with a Gatan slow scan CCD camera (Pleasanton, Calif.). The samples were prepared either by scratching the films from silicon substrates using a cutting blade or by using standard cross-section techniques.
- the x-ray diffraction pattern of a lipid-silica assembly made using the standard Egg PC can be seen in FIG. 3A .
- the x-ray diffraction pattern of a lipid-silica assembly made using Egg PC and cholesterol can be seen in FIG. 3B .
- the lipid-silica assembly made using Egg PC alone had a d-spacing of 48-50 ⁇ acute over ( ⁇ ) ⁇ with only two peaks in the X-ray diffraction pattern.
- Transmission electron microscopy revealed the structure to be lamellar.
- the addition of cholesterol to the Egg PC-silica assembly increased the order of the x-ray diffraction pattern with new peaks at 31 ⁇ acute over ( ⁇ ) ⁇ and 16 ⁇ acute over ( ⁇ ) ⁇ suggesting the phase separation of the cholesterol-silica assembly ( FIG. 3B ).
- peaks appeared at 31 ⁇ acute over ( ⁇ ) ⁇ and 16 ⁇ acute over ( ⁇ ) ⁇ corresponding closely to a cholesterol bilayer that has a thickness of 33.9 ⁇ acute over ( ⁇ ) ⁇ .
- Lipids with the same chain length but different head groups were used to prepare lipid-silica assemblies with a 2.5 wt % lipid composition.
- Lipid silica assemblies were prepared using DMPC, DMPE, DMPG, DMPS, DOPE, DOPA and DOPC respectively, all of which were obtained from Avanti Polar Lipids (Alabaster, Ala.).
- the lipids were prepared by hydrating each of them with stock sol of Example I for 1 hour.
- the resulting mixtures were then individually homogenized by vortexing for 5 minutes at room temperature and then subjected to sonication for 5 minutes at room temperature using a VWR bath sonicator (power rating-9) (VWR International, West Chester, Pa.) before being coated at a speed of 3000 RPM for one minute onto silicon wafers which had previously been cleaned with a piranha solution of a 3:1 mixture of sulfuric acid and 30% hydrogen peroxide.
- VWR bath sonicator power rating-9 (VWR International, West Chester, Pa.)
- Lipid DOPE and EggPC in chloroform (Avanti Polar Lipids (Alabaster, Ala.)) were combined in a 1:1 ratio and hydrated for one hour with the stock sol of Example I. Aliquots of the resulting mixture were then homogenized by vortexing for 5 minutes at room temperature and then either coated directly onto silicon wafers or subjected to sonication for 5 minutes in an ice bath using a VWR bath sonicator (power rating-9) (VWR International, West Chester, Pa.) before being coated at a speed of 3000 RPM for one minute onto silicon wafers which had previously been cleaned with a piranha solution of a 3:1 mixture of sulfuric acid and 30% hydrogen peroxide.
- VWR bath sonicator power rating-9 (VWR International, West Chester, Pa.)
- the resulting films were characterized using X-ray diffraction and transmission electron microscopy.
- Transmission electron microscopy was performed using a JEOL 2010 (Tokyo, Japan) with 200 kv accelerating voltage equipped with a Gatan slow scan CCD camera (Pleasanton, Calif.). The samples were prepared either by scratching the films from silicon substrates using a cutting blade or by using standard cross-section techniques.
- FIG. 7A provides a comparison of the x-ray diffraction pattern of the sonicated (upper line) and unsonicated samples (lower line).
- bR-containing purple membranes composed primarily of phosphatidylglycerosulphate methyl ester and 3-HSO 3 -Galp- ⁇ 1, 6-Manp- ⁇ -1,2-Glcp- ⁇ 1, 1-sn-2,3-diphytanylglycerol (Munich innovative Biomaterials GmbH, Germany) were combined with dried DOPE (Avanti Polar Lipids (Alabaster, Ala.)) at a ratio of 1:100. The resulting powder was then hydrated for one hour with stock sol from Example I. The resulting mixture was then homogenized by vortexing for 5 minutes at room temperature.
- DOPE Advanti Polar Lipids
- the homogenized mixture was then either coated onto silicon wafers as it was, or subjected to sonication for 5 minutes at room temperature using a VWR bath sonicator (power rating-9) (VWR International, West Chester, Pa.) before being coated onto silicon wafers. Both solutions were coated at a speed of 3000 RPM for one minute onto silicon wafers which had previously been cleaned with a piranha solution of a 3:1 mixture of sulfuric acid and 30% hydrogen peroxide.
- the resulting films were characterized using X-ray diffraction and transmission electron microscopy.
- Transmission electron microscopy was performed using a JEOL 2010 (Tokyo, Japan) with 200 kv accelerating voltage equipped with a Gatan slow scan CCD camera (Pleasanton, Calif.). The samples were prepared either by scratching the films from silicon substrates using a cutting blade or by using standard cross-section techniques.
- FIG. 8A the TEM micrograph of a bR-DOPE-silica thin film without sonication shows the presence of multi-lamellar vesicle like structures.
- the x-ray diffraction pattern of the same film shows two distinct peaks of different d-spacing with one peak corresponding to a d-spacing of ⁇ 46 ⁇ acute over ( ⁇ ) ⁇ and another peak corresponding to 53 ⁇ acute over ( ⁇ ) ⁇ .
- Analysis of a film prepared with a solution treated to sonication reveals planar lamellar structures (8B) and x-ray diffraction revealed a single d-spacing of ⁇ 46 ⁇ acute over ( ⁇ ) ⁇ .
- the purple membrane is composed primarily of phosphatidylglycerosulphate methyl ester and 3-HSO 3 -Galp- ⁇ 1, 6-Manp- ⁇ 1,2-Glcp- ⁇ 1,1-sn-2, 3-diphytanylglycerol which generally creates a high negative charge density on the membrane surfaces and can therefore inhibit the formation of ordered lamellar structures.
- the inclusion of purple membrane components with the DOPE formulation results in the formation of multi-lamellar vesicle like structures.
- Gramicidin (Sigma Aldrich (St. Louis, Mo.)) was combined with dried DOPE (Avanti Polar Lipids (Alabaster, Ala.)) at a ratio of 1:10. The resulting powder was then hydrated for one hour with stock sol from Example I. The resulting mixture was then homogenized by vortexing for 5 minutes at room temperature. The homogenized mixture was then either coated onto silicon wafers as it was, or subjected to sonication for 5 minutes at room temperature using a VWR bath sonicator (power rating-9) (VWR International, West Chester, Pa.) before being coated onto silicon wafers. Both solutions were coated at a speed of 3000 RPM for one minute onto silicon wafers which had previously been cleaned with a piranha solution of a 3:1 mixture of sulfuric acid and 30% hydrogen peroxide.
- TEM transmission electron microscopy
- Transmission electron microscopy was performed using a JEOL 2010 (Tokyo, Japan) with 200 kv accelerating voltage equipped with a Gatan slow scan CCD camera (Pleasanton, Calif.). The samples were prepared either by scratching the films from silicon substrates using a cutting blade or by using standard cross-section techniques.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present disclosure provides various novel methods for forming hybrid thin films that contain multi-lamellar assemblies of phospholipid bilayers and can incorporate proteins, polypeptides, biological complexes, transmembrane proteins and other membrane-associated compounds. The present disclosure further provides uses for such bilayer lipid membranes including, biosensing for medical diagnosis and environmental monitoring, chemical and biological warfare agent sequestration, actuator development, and bio-fuel cell development.
Description
- The following application is a divisional application of U.S. patent application Ser. No. 11/690,922, filed Mar. 26, 2007, which claims the benefit of U.S. Provisional Application Nos. 60/785,699, filed Mar. 24, 2006, and 60/786,120, filed Mar. 27, 2006, each of which is hereby incorporated by reference in its entirety.
- Aspects of this work were supported by a grant from the Department of the Army through grant no. DAAD19-03-1-0173. The United States Government has certain rights in the subject matter.
- The present invention relates to hybrid thin films. More specifically the present invention relates to methods for incorporating polypeptides, biological complexes, transmembrane proteins and other membrane-associated components into hybrid thin films and methods of using the same.
- Phospholipids are a major component of all biological membranes. In its simplest form, a phospholipid is composed of glycerol bonded to two fatty acids and a phosphate group. Due to its polar nature, the head of a phospholipid is hydrophilic while the nonpolar tails are hydrophobic. When placed in water, phospholipids form a bilayer, composed of a hydrophobic core region formed by the acyl chains of the lipids, and hydrophilic membrane interfacial regions that are formed by the polar head groups of the lipids.
- Membranes made of phospholipid bilayers are partially permeable, very flexible, and have fluid properties in which embedded proteins and phospholipid molecules are constantly moving laterally across the membrane. Proteins incorporated into the phospholipid bilayer can facilitate actions such as compartmentalization, passive and active transport, signal transduction, specific recognition, and energy utilization.
- Because of their versatility in function, scientists have long sought to incorporate phospholipid bilayer membranes into artificial materials and devices. These devices have a broad range of potential applications including ligand based biosensors for clinical diagnostics; memory devices; screening devices for pharmaceutical applications; the provision of biologically functionalized surfaces; binding sites for small molecules such as drugs, pesticides, molecules required to be analyzed during process control (i.e. food stuffs, fermenter products, chemicals); larger molecules such as proteins for research screening (e.g. array technology) or diagnostics (cancer markers, infectious disease markers, hormones); nucleic acids; carbohydrate polymers; cells such as pathogenic bacteria; eukaryotic cells such a cancer cells and small single or multicellular organisms especially parasites; high throughput screening for pharmaceutical applications; controlled drug delivery; medical diagnosis; environmental monitoring, chemical and biological warfare agent sequestration; actuator development; power sources; electrochemical pumps; and bio-fuel cell development.
- However, phospholipid bilayer membranes are inherently fragile. Due to their thinness, polar charge, tendency to naturally curve, and the inherently weak self-assembly forces at work, they are subject to disruption from phenomenon such as vibration, sonication, chemical reaction, pH, temperature denaturing, electromagnetic fields and the like making them unsuitable for applications outside of the most stringently controlled conditions. Additionally, it has been difficult to create membranes with uniform nanostructures capable of incorporating other proteins such as transmembrane proteins in nonrandom orientations.
- There is therefore a need for the creation of stable membranes capable of mimicking natural biological processes. There is additionally a need for the creation of stable membranes which contain uniform nanostructures amenable to the incorporation of biomolecular complexes in nonrandom orientations.
- The present disclosure provides various novel methods for forming hybrid thin films that contain multi-lamellar assemblies of phospholipid bilayers and can incorporate proteins, polypeptides, biological complexes, transmembrane proteins and other membrane-associated compounds. The present disclosure further provides uses for such bilayer lipid membranes including, biosensing for medical diagnosis and environmental monitoring, chemical and biological warfare agent sequestration, actuator development, and bio-fuel cell development.
-
FIGS. 1A and B show TEM micrographs of the surface and the x-ray diffraction pattern (inset) of a lipid-silica thin film (2.5 wt % lipid in stock sol) made with (A) 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and (B) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). -
FIG. 2 is the x-ray diffraction pattern of 2.5% wt lipid-water-ethanol coated film on silicon wafer made using DMPC. -
FIG. 3 shows the x-ray diffraction pattern of lipid EggPC-silica thin film (2.5 wt % lipid in stock sol) (A) before the addition of cholesterol and (B) after the addition of cholesterol (4:1 EggPC:cholesterol). -
FIGS. 4 A and B are x-ray diffraction patterns of 2.5 wt % lipid-silica assemblies made using (A) saturated or (B) unsaturated lipids. -
FIG. 5 shows the x-ray diffraction pattern of 2.5 wt % lipid-silica assemblies made using a 1:1 combination of EggPC and DOPE before sonication and after sonication. -
FIGS. 6A and B are micrographs of the surface of DOPE-silica thin films prepared with (A) 10 wt % DOPE in stock sol and (B) lwt % DOPE. -
FIG. 6C is the X is the x-ray diffraction pattern of DOPE-silica films prepared from 10, 5.0, 2.5, 1 and 0.1 wt % DOPE. -
FIGS. 7A and B are images of the results of vesicle entrapment in lipid-silica assemblies made using EggPC taken using (A) TEM and (B) x-ray diffraction. -
FIGS. 8 A and B are TEM micrographs of DOPE-silica thin films prepared from 2.5 wt % DOPE and bacteriorhodopsin in a 100:1 DOPE:bR ratio (A) without sonication and (B) with sonication. -
FIG. 8 C is an x-ray diffraction pattern of DOPE-silica thin films prepared from 2.5 wt % DOPE and bacteriorhodopsin in a 100:1 DOPE:bR ratio with and without sonication. -
FIG. 9 shows the x-ray diffraction patterns of DOPE-silica thin films (A) with sonication, (B) without sonication, (C) with gramicidin but without sonication and (D) with gramicidin and sonication. -
FIG. 9B is the transmission IR spectrum of gramicidin-DOPE-silica assemblies prepared with a 10:1 lipid:peptide ratio. -
FIG. 10 is the x-ray diffraction pattern for lipid-silica matrices demonstrating that the positions of the diffraction peaks were in integer multiples indicating the lamellar nature of CTAB in the silica matrix. - The present invention provides methods for preparing hybrid bioorganic-inorganic thin films with specific architecture. Such thin films can be used in a variety of applications including, but not limited to, biosensors, medical diagnosis, environmental monitoring, chemical and biological warfare agent sequestration, actuator development, power sources, sensing platforms, electrochemical pumps, and bio-fuel cell development.
- The present invention further provides methods for preparing hybrid bioorganic-inorganic thin films that can exhibit selective and active transport function.
- The present invention additionally provides methods for preparing functional biosynthetic cell membrane components encapsulated in nanostructured membrane architectures.
- Phospholipid bilayer membranes are essential components of cellular systems. They enable a variety of functions including compartmentalization, passive and active transport, signal transduction, specific recognition and energy utilization. Formation of phospholipid bilayers is influenced by factors such as the surfactant used, pH, salt concentration, type of solvent and temperature at which the assemblies are synthesized.
- The thin films formed by the methods herein are artificial assemblies which self assemble with phospholipids and phospholipid mixtures into micellar and lyotrophic liquid crystalline phases. For example, in some embodiments, a lamellar structure may be constructed in which hydrophilic crosslinked polymer nanophases are separated by parallel lipid bilayers. In additional embodiments, the lamellae are parallel to the film surface. In other embodiments, the lamellar assemblies are highly ordered. The thin films contain uniform nanostructures that are amenable to the incorporation of functional amphiphilic proteins, peptides and other biomolecular complexes in nonrandom orientations.
- The nanostructures created by the methods of the present invention may be planar or vesicle like. In some embodiments, the structures exhibit uniform d-spacing of between 35 to 48{acute over (Å)}. In other embodiments the uniform d-spacing is 44{acute over (Å)}. In additional embodiments, the polymer and phospholipid bilayers may alternate. In further embodiments, processing conditions may be altered to effect the orientation of the transmembrane protein or other biomolecular complex.
- The scale of these thin films may be from about 5 to about 500 nm, about 5 to about 100 nm or about 5 to about 50 nm in width. In another embodiment, liposomes may be formed using lipid-polymer hybrid membranes. These liposomes may be about 40 nm to about 100 nm, and more preferably about 50 to about 100 nm. Thin films incorporating phospholipid bilayer assemblies may be constructed using saturated or unsaturated lipids with a packing fraction parameter of between 0.5 to 1. In some embodiments, the thin films may contain highly ordered lyotrophic crystalline surfactant phases encapsulated in rigid silica matrices.
- The thin films of the present invention are generally formed using a precursor sol, solvent, acid, water and dried phospholipids. The precursor sol may be formed by combining a polymer or hydrogel, a solvent, and water. Exemplary polymers for use within the methods and compositions of the present invention include, but are not limited to, inorganic polymers such as tetramethylorthosilicate, tetraethylorthosilicate, aminopropyltrimethyoxysilane, hydroxymethyltriethoxysilane, methacryloxypropyl trimethoxysilane, and hydroxyethyl methacrylate; organic polymers including non-ionic organic polymers such as poly (vinyl alcohol), poly (vinyl pyrrolidone), poly (ethylene oxide), hydroxy-propyl cellulose, dextran, agarose, dissacharides: sucrose, glucose and trehalose; anionic organic polymers such as poly (acrylic acid), poly (sodium styrene sulphonate), poly acrylamide (PAM), alignate, chitosan-EDTA, carbomer, pectins, DNA; cationic organic polymers including, but not limited to, poly(diallyldimethylammonium chloride), chitosin, and poly-lysine or combinations thereof. The polymer precursors impart toughness and rigidity to the membranes while the hydrogel precursors provide a highly water swollen matrix that is believed to facilitate diffusion of water soluble analyte species. Exemplary solvents include alcohols such as, for example, ethanol, methanol, and isopropyl alcohol. Exemplary acids include HCl.
- In some embodiments, the polymer may be silica based. Exemplary silicas include, but are not limited to, tetraalkoxysilanes such as tetraethylorthosilicate or tetramethyl-orthosilicate; trialkoxysilane such as aminopropyltrimethyoxysilane, hydroxymethyltriethoxysilane or methacryloxypropyl trimethoxysilane; or combinations thereof. Such polymers form a matrix, for example through a siloxane condensation reaction, whose nanostructure may be determined by the organized lipid structures.
- In additional embodiments, surfactant may be added to the precursor sol. Any surfactant which forms a lamellar structure in the polymer matrix may be used. The lamellar nature of the surfactant may be determined by any means applicable. In one embodiment the structure of a film constructed using a surfactant may be determined through x-ray diffraction as seen in
FIG. 10 .FIG. 10 depicts the x-ray diffraction pattern for a highly ordered nano structured silica/surfactant membrane prepared using cetyltrimethyl ammonium bromide (CTAB), aminopropyltrimethoyoxysilane and the exemplary phospholipids listed below. The positions of the diffraction peaks inFIG. 10 are in integer multiples indicating the lamellar nature of CTAB in the silica matrix. - Exemplary surfactants for use within the compositions and methods of the present invention include, but are not limited to, ionic surfactants such as cetyltrimethyl ammonium bromide (CTAB), and nonionic surfactants such as Pluronic-P 123 (poly(ethylene oxide E0)20(propylene oxide P0)70(E0)20).
- Lipids for use within the methods and compositions of the present invention may include saturated or unsaturated lipids. The selection of particular lipids and the concentration of lipids may depend in part on the type of resulting thin film and nanostructures to be obtained. In some embodiments, the lipids form 0.01-50% wt of the resulting solution. In other embodiments, the lipids from between about 1 to 30% wt, preferably about 5 to 20% wt, more preferably about 5 to 10% wt, more preferably 0.01 to about 10% weight of the resulting solution. The concentration of the lipids may effect the d spacing of the lamellar structures. In some embodiments, an increase in the concentration of the lipid may be used to increase the d spacing in the resulting nanostructures.
- The selection of a particular lipid may be based on a number of factors including, but not limited to, the packing coefficient, charge, the length of the tails, and the number of chains per headgroup. Potential structures may be predicted by determining the packing parameters of the lipids used to construct the membranes. Different packing parameters or shape factor g (vhc/aolc) of amphiphiles, where ao is the optimal head group area, lc is the critical length of the hydrocarbon chain, and vhc is the volume of hydrocarbon chains, may be used to predict or interpret the microstructure of lipid-polymer assemblies. Different parameters may generate lamellar, hexagonal or cubic structures. For example, a lamellar phase, such as that created by the methods of the present invention, is obtained when the packing fraction parameter is between 0.5 to 1.
- The packing parameter of DMPC is calculated to be 0.577 using the equations and values given below
-
V hc=2·[(n c−2)·v CH2 +v CH3] - The head group area for a PC molecule is estimated to be 62{acute over (Å)}2. Vhc is the hydrocarbon chain volume of the two acyl chains with vCH2=27{acute over (Å)}3 and vCH3=54 {acute over (Å)}3. The maximum extended chain length of the phospholipids is given by the relation
-
1c=1.25(n−1)+0.85+d - where d is the displacement of the chains. (4{acute over (Å)}) (Kleinschrnidt, J. H.; Tamm, L. K.; Biophysical Journal 2002, 83 994-1003).
- Using these values, the packing fraction parameter for the lipid DMPC is as follows:
-
g=v hc /a o lc=0.577 - However, using the methods of the present invention, the head group area, ao is effectively increased by approximately 10% due to the positive charge on the DMPC molecule at pH 2.2, where the phosphate group is protonated. The net packing parameter of DMPC molecule with pH factor taken into account is therefore as follows:
-
g=v hc /a o l c=0.525 - indicating the possibility of the formation of lamellar phase in DMPC-polymer assemblies.
- Packing parameters vary depending on whether saturated or unsaturated lipids are used. The contrast in the packing parameters of saturated and unsaturated lipids in the hybrid phospholipid-silica thin film assemblies of the present invention can be seen, for example, in a comparison of
FIGS. 1A and 1B . InFIG. 1A , d spacing observed for film created using DMPC is 42 to 44 {acute over (Å)}. Four order of diffraction peaks are observed for saturated lipids with a peak ratio is 1:2:3:4. InFIG. 1B , d spacing for a film created using DOPE is approximately 47 {acute over (Å)} with a first order diffraction peak at 47 {acute over (Å)} and a second order peak at 24 Å. These results indicate that the saturated lipids are better packed than unsaturated lipids. - The length of the lipid chain also influences the end structure of the thin film. As demonstrated in the examples below, lipids with chain lengths of 14 carbon atoms yield a d-spacing of 42-44 {acute over (Å)} whereas lipids with a chain length of 18 carbon atoms yield a d-spacing of 47-49 Å. It was therefore determined that there was an increase in d-spacing of approximately 1.2 {acute over (Å)} for each carbon added to the chain.
- The structure of thin films may additionally be influenced by the number of chains per headgroup. Thin films were prepared as detailed in the examples below using MHPC, DMPC, and cardiolipin, three saturated lipids each with a chain length of 14 carbon atoms. MHPC is a single tailed lipid, DMPC has two chains and cariolipin has 4 chains. The d-spacing observed for the three lipids was 42 {acute over (Å)}, 44{acute over (Å)} and 46{acute over (Å)} respectively. The difference in the spacing may be explained by the stiffness of the hydrocarbon tails with single chain lipids having more flexible tails.
- Additionally, as can be seen in
FIG. 4 , the charge of the headgroup effects membrane formation. Lipids with a positively charged headgroup at pH 2.2 and lipids capable of hydrogen bonding yield lamellar-lipid silica assemblies of the present invention, whereas lipids with neutral or negatively charged headgroups failed to form the desired structures. While not wishing to be bound, it is currently theorized that the charge may influence the effective size of the head group of the lipid, thereby altering the packing parameter and hence the formation of the lipid assembly. - Exemplary phospholipids for use within the invention include, but are not limited to, 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC; 14:0); 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE; 14:0); 1,2-dimyristoyl-sn-g/ycero-3-[phospho-rac-(1-glycerol)] (Sodium Salt)(DMPG, 14:0); 1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine (14:O Lyso PC); 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC; 18:1 (cis)); 1-oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (18:1 Lyso PE); 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE, 18:1); L-phosphatidylcholine (Egg, Soy); Phosphatidylcholine (NBD); 1,1′,2,2′-tetramyristoyl cardiolipin (Ammonium Salt) (14:0); lipids with head groups phosphatidyl serine and phosphatidylinositol; poly(ethylene glycol)-lipid conjugates; and fluoroscent lipids-phosphatidylcholine (NBD) or combinations thereof. In some embodiments, cholesterol may be added to mixtures containing unsaturated lipids. Cholesterol may be added to the dried lipid, the precursor sol, or a combined mixture of dried lipid and precursor sol in varying concentrations from about 0 to 50% weight of the lipid mixture, preferably about 10 to 40% weight, more preferably about 15 to 30% weight.
- The selected lipids are hydrated in the precursor sol to form a lipid-polymer solution. The resulting solution may be homogenized. Such a homogenized solution may be further treated, for example, through sonication or extrusion.
- Such solutions, regardless of homogenization, may then be used to form the hybrid thin films of the present invention. In some embodiments, such thin films may further incorporate additional biomolecular complexes including transmembrane proteins which may be used in the transport of solutes. Such biomolecular complexes may be incorporated with specific orientations. The particular orientation of a biomolecular complex may be varied depending on the conditions used. Such variation may effect the flow of the analyte species transported by the biomolecular complex.
- In previous artificial membranes, the transport rate of aqueous solutes, particularly larger ions and molecules was inhibited by dense cros slinking of polymers between the lipid bilayer structures. The degree of cros slinking in embodiments of the present invention may be reduced by changing the condensation conditions or through the incorporation of comonomers into the precursor sol that are not capable of quadravalent bonding. Exemplary comonomers as used in the present invention include, but are not limited to, aminopropltrimethoxysilane, hydroxymethyltriethotysilane and methacryloxypropyl trimethoxysilane.
- The resulting synthetic and hybrid biosynthetic membranes of the present invention have unprecedented levels of specificity towards aqueous solutes. In addition to selective ion channels and molecular channels, the membrane systems of the invention can include transmembrane proteins that are involved in active transport by proton, ion and molecular pumping mechanisms.
- Biomolecular complexes may be included in the membranes by combining the lipids with additional proteins or peptides prior to hydration. In other embodiments, such biomolecular complexes may be included by adding them directly to the precursor sol either before or after the addition of lipids.
- Exemplary biomolecular complexes including proteins and peptides that may be incorporated into the hybrid thin films of the present invention include, but are not limited to, g protein coupled receptors including, but not limited to, Class A (Rhodopsin-like) G protein coupled receptors which bind amines, peptides, hormone proteins, rhodopsin, olfactory prostanoid, nucleotide-like compounds, cannabinoids, platelet activating factor, gonadotropin-releasing hormone, thyrotropin-releasing hormone and secretagogue, melatonin and lysosphingolipid and LPA; G protein coupled receptors with amine ligands including, but not limited to, acetylcholine or muscarinic, adrenoceptors, dopamine, histamine, serotonin or octopamine receptors; peptide ligands including, but not limited to, angiotensin, bombesin, bradykinin, anaphylatoxin, Finet-leu-phe, interleukin-8, chemokine, cholecystokinin, endothelin, melanocortin, neuropeptide Y, neurotensin, opioid, somatostatin, tachykinin, thrombin vasopressin-like, galanin, proteinase activated, orexin and neuropeptide FF, adrenomedullin (G10D), GPR37/endothelin B-like, chemokine receptor-like and neuromedin U; hormone protein, rhodopsin, olfactory, prostanoid, nucleotide-like (adenosine, purinoceptors), cannabinoid, platelet activating factor, gonadotropin-releasing hormone, thyrotropin-releasing hormone and secretagogue, melatonin, lysosphingolipid, and LPA; Class B secretin-like g protein coupled receptors including, but not limited to, those which bind calcitonin, corticotropin releasing factor, gastric inhibitory peptide, glucagon, growth hormone-releasing hormone, parathyroid hormone, PACAP, secretin, vasoactive intestinal polypeptide, diuretic hormone, EMR1 and latrophilinl; class C metabotropic glutamate receptors including, but not limited to, those which bind metabotropic glutamate, extracellular calcium-sensing or GABA-B; receptor kinases; ion channels including, ionophores such as gramicidin, almaethicin, valinomycin, arnphotericin B, and colcins; ligand gated channels such as acetylcholine receptor, glycine and GABA receptor, cytochrome oxidase, seratonin receptor, and IgE receptors; voltage gated channels such as, Na+ ion channel, K+ ion channel, chloride channel, and Ca2+ ion channel; light gated channels such as rhodopsin, and channelopsinl; active transport systems including, but not limited to, bacteriorhodopsin, Ca2+-ATPase, Na+/K+ ATPase, Na+-Glucose cotransport (Secondary), and H+/K+ ATPase ABC Transporters; porins, including alpha-hemolysin; and toxins such as diptheria and cholera toxins.
- In some embodiments, the incorporated functioning protein may be bacteriorhodopsin. Bacteriorhodopsin (bR) is a 26 kDa transmembrane protein that uses a photochemical process to transport protons across the cell membrane against an electrochemical potential of up to 250 mV, translating to a 105 fold difference in proton concentration across the membrane. It is considered to be a prototype for a class of membrane transporters and also serves as a structural model for the G-protein-coupled receptors. (J.-P. Cartailler and H. Luecke, Annu. Rev. Biophys. Biomol. Struct. 326, 1317 (2003))
- In another embodiment, the incorporated functioning protein may be gramicidin. Gramicidin is a model ion channel with alternating D and L amino acids. Gramicidin dimerizes to from a conductive state where two 15-amino acid peptides forming B-helices meet head to head at their N-termini in the interior of a lipid bilayer. The outer surface of the gramicidin that interacts with the lipids is hydrophobic in nature, and only monovalent cations pass through the more polar core of the helix. (A. Finkelstein and O. S. Andersen, J. Membr. Biol. 59, 155 (1981))
- The hydrated polymer-lipid or polymer-lipid-biomolecular complex solution may additionally be coated onto a solid support. Coating may occur using any method known to those with skill in the art. In some embodiments, the solution is spin coated. In other embodiments, the solution is dip coated. In further embodiments, the solution may be deposited on a solid support using a combination of spin and dip coating. Solid supports may be macro or mesoporous. Exemplary solid supports include, but are not limited to, silicon wafer, silane-silicon, self assembled monolayer-gold, SnO2, polymer coated substrates, gold, gold-SAM, or porous Alumina. Furthermore, solid supports may be planar or non-planar and formed as wafers or chips with regular or irregular surfaces, beads, microstructures, etc.
- After coating, preferential evaporation of the solvent results in a concentration of lipids in a manner that allows their self-assembly into micellar and lyotropic liquid crystalline phases while a polymer matrix forms based on the organization of the lipid structures.
- The formation of uniform nanonstructures in the hybrid membranes of the present invention may be determined by any means applicable. In some embodiments, such determinations may be made using x-ray diffraction technology. Uniform nanostructures will generate regular d-spacings. In another embodiment, transmission electron microscopy may be used to determine the structure of the membranes. In a further embodiment, the orientation of functioning proteins may be examined by polarized Fourier transform infrared spectroscopy or secondary ion mass spectrometry.
- The functioning of the incorporated proteins may be determined by any means applicable. For example, changes in hydrogen ion flux such as with the incorporation of gramicidin may be determined by impedence analysis. Ion sensitive fluorescent dies may be used to track gradients in ionic concentration. Electrophoretic mobility of ions through the hybrid membranes may also be characterized. Theoretical models of membrane transport may be used to calculate diffusion constants of ions, thus allowing quantitative comparisons between different membrane formulations. Additionally, membrane permeability in complex aqueous environments may also be determined. In a further embodiment, light induced pH changes caused by the proton pumping action of light activated proteins such as bacteriorhodobsin may be measured using pH meters and pH sensitive fluorescent dyes such as SNAFL-2 or fluorescein.
- The specific methods and compositions described herein are representative of preferred embodiments and are exemplary and not intended as limitations on the scope of the invention. Other objects, aspects, and embodiments will occur to those skilled in the art upon consideration of this specification, and are encompassed within the spirit of the invention as defined by the scope of the claims. It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, or limitation or limitations, which is not specifically disclosed herein as essential. The methods and processes illustratively described herein suitably may be practiced in differing orders of steps, and that they are not necessarily restricted to the orders of steps indicated herein or in the claims.
- As used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to “a host cell” includes a plurality (for example, a culture or population) of such host cells, and so forth.
- The terms and expressions that have been employed are used as terms of description and not of limitation, and there is no intent in the use of such terms and expressions to exclude any equivalent of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention as claimed. Thus, it will be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.
- The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
- The following examples illustrate certain embodiments of the present invention, and are not to be construed as limiting the present disclosure. The evidence provided in these examples demonstrates methods based on sol-gel processing from the formation of robust thin films that incorporate phospholipid bilayer membranes and transmembrane proteins as multilamellar assemblies in cross-linked silica matrices.
- Tetraethyl otrthosilicate (TEOS), ethanol, deionized water, and 0.07 N HCl were mixed in the molar ratio of 1.0 TEOS:3.8 C2H5OH: 1.0 H2O: 5×10−5 HCL and refluxed at 60° C. for 90 minutes. The resulting solution was diluted with 4 ml ethanol (1:2) followed by the addition of approximately 0.16 ml water and dilute 0.07 N HCl.
- Various saturated and unsaturated lipids were used to prepare hybrid phospholipid-silica thin film assemblies by spin coating a mixture of lipids and a silica sol on silicon wafers. The following lipids, obtained from Avanti Polar Lipids (Alabaster, Ala.), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC; 14:0); 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE; 14:0); 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (Sodium Salt) (DMPG, 14:0); 1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine (14:0 Lyso PC); 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC; 18:1 (cis)); 1-oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (18:1 Lyso PE); 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE, 18:1); L-α-phosphatidylcholine (Egg) and 1,1′,2,2′-tetramyristoyl cardiolipin (Ammonium Salt) (14:0), were prepared by evaporating the chloroform under a stream of nitrogen followed by desiccation under vacuum for at least 12 hrs.
- Between 0.01 wt % to 10 wt % (typically from 0.1 mg to 100 mg of lipid) of dry phospholipids were added to the samples of the stock sol of Example I and hydrated for 1 hour. Each hydrated lipid solution was then homogenized by vortexing for 5 minutes at room temperature. The resulting solutions were then subjected to sonication for 5 minutes at room temperature using a VWR bath sonicator (power rating-9) (VWR International, West Chester, Pa.) before being coated at a speed of 3000 RPM for one minute onto silicon wafers which had previously been cleaned with a piranha solution of a 3:1 mixture of sulfuric acid and 30% hydrogen peroxide.
- The resulting films were characterized using X-ray diffraction and transmission electron microscopy. X-ray diffraction was performed using a Siemens D500 diffractometer (NY, N.Y.) using Ni filtered CuKα radiation with λ-1.5406{acute over (Å)} in θ-2θ(2θ=0.8°-8.0° step-scan mode using a step size 0.02° for 3 seconds. Transmission electron microscopy was performed using a JEOL 2010 (Tokyo, Japan) with 200 kv accelerating voltage equipped with a Gatan slow scan CCD camera (Pleasanton, Calif.). The samples were prepared either by scratching the films from silicon substrates using a cutting blade or by using standard cross-section techniques.
- As can be seen in
FIG. 1A , which is representative of more than 25 samples, the d spacing observed for the film created using DMPC is 42 to 44 {acute over (Å)}. Four order of diffraction peaks are observed for saturated lipids and the peak ratio is 1:2:3:4 exhibiting lamellar structure. Additionally, the x-ray diffraction pattern is most consistent with a lamellar phase structure with alternating phospholipid and silica layers that are parallel to the film surface. - Further confirmation of a lamellar phase structure was determined by aging samples for 2 weeks for the condensation to take place. The samples were then subjected to calcination for four hours at 400° C. (heating rate of 1° C. per minute). Analysis of films that had been subjected to calcination revealed no peaks in the x-ray diffraction pattern indicating the collapse of the structure. Such a collapse is indicative of a lamellar formation.
- 2.5 mg of DMPC was dissolved in 500 ethanol and 500 water (pH 2.2) for one hour. The resulting solution was then coated onto silicon wafers.
- As can be seen in
FIG. 2 , the d-spacing obtained for the lipid-water system is 48{acute over (Å)}. The peaks are in a ratio of 1:2:3:4:5 demonstrating the lamellar structure of alternating lipid and water layers. - Preparations made with 2.5 mg of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) dissolved in 500 ethanol and 500 μl water (pH 2.2) for one hour and coated onto silicon wafers yielded inconsistent films with no definitive d spacing.
- Egg phosphatidylcholine (Egg PC) is a mixture of phosphatidylcholines that differ in their fatty acid composition. The formulation used in this experiment was obtained from Avanti Polar Lipids (Alabaster, Ala.) and has a fatty acid distribution of 16:0 (34%), 16:1(2%), 18:0(11%), 18:1(32%), 18:2(18%), 20:4 (3%).
- Lipid silica assemblies were prepared using Egg PC alone, cholesterol alone and varying mixtures of Egg PC and cholesterol. The Egg PC was prepared by hydrating Egg PC with stock sol of Example I for 1 hour. From 5 mol % to 50 mol % of cholesterol were added to aliquots of the hydrated Egg PC. The resulting mixtures were then individually homogenized by vortexing for 5 minutes at room temperature and then subjected to sonication for 5 minutes at room temperature using a VWR bath sonicator (power rating-9) (VWR International, West Chester, Pa.) before being coated at a speed of 3000 RPM for one minute onto silicon wafers which had previously been cleaned with a piranha solution of a 3:1 mixture of sulfuric acid and 30% hydrogen peroxide.
- The resulting films were characterized using X-ray diffraction and transmission electron microscopy. X-ray diffraction was performed using a Siemens D500 diffractometer (NY, N.Y.) using Ni filtered CuKα radiation with λ-1.5406{acute over (Å)} in θ-2θ) (2θ=0.8°-8.0° step-scan mode using a step size 0.02° for 3 seconds. Transmission electron microscopy was performed using a JEOL 2010 (Tokyo, Japan) with 200 kv accelerating voltage equipped with a Gatan slow scan CCD camera (Pleasanton, Calif.). The samples were prepared either by scratching the films from silicon substrates using a cutting blade or by using standard cross-section techniques.
- The x-ray diffraction pattern of a lipid-silica assembly made using the standard Egg PC can be seen in
FIG. 3A . The x-ray diffraction pattern of a lipid-silica assembly made using Egg PC and cholesterol can be seen inFIG. 3B . - As seen in
FIG. 3A , the lipid-silica assembly made using Egg PC alone had a d-spacing of 48-50{acute over (Å)} with only two peaks in the X-ray diffraction pattern. Transmission electron microscopy revealed the structure to be lamellar. The addition of cholesterol to the Egg PC-silica assembly increased the order of the x-ray diffraction pattern with new peaks at 31 {acute over (Å)} and 16 {acute over (Å)} suggesting the phase separation of the cholesterol-silica assembly (FIG. 3B ). When cholesterol alone was used, peaks appeared at 31 {acute over (Å)} and 16 {acute over (Å)}, corresponding closely to a cholesterol bilayer that has a thickness of 33.9 {acute over (Å)}. - Lipids with the same chain length but different head groups were used to prepare lipid-silica assemblies with a 2.5 wt % lipid composition. Lipid silica assemblies were prepared using DMPC, DMPE, DMPG, DMPS, DOPE, DOPA and DOPC respectively, all of which were obtained from Avanti Polar Lipids (Alabaster, Ala.). The lipids were prepared by hydrating each of them with stock sol of Example I for 1 hour. The resulting mixtures were then individually homogenized by vortexing for 5 minutes at room temperature and then subjected to sonication for 5 minutes at room temperature using a VWR bath sonicator (power rating-9) (VWR International, West Chester, Pa.) before being coated at a speed of 3000 RPM for one minute onto silicon wafers which had previously been cleaned with a piranha solution of a 3:1 mixture of sulfuric acid and 30% hydrogen peroxide.
- The resulting films were characterized using X-ray diffraction and transmission electron microscopy. X-ray diffraction was performed using a Siemens D500 diffractometer (NY, N.Y.) using Ni filtered CuKα radiation with λ-1.5406{acute over (Å)} in θ-2θ) (2θ=0.8°-8.0° step-scan mode using a step size 0.02° for 3 seconds. Transmission electron microscopy was performed using a JEOL 2010 (Tokyo, Japan) with 200 kv accelerating voltage equipped with a Gatan slow scan CCD camera (Pleasanton, Calif.). The samples were prepared either by scratching the films from silicon substrates using a cutting blade or by using standard cross-section techniques.
- Lipid-silica assemblies made with saturated lipids, DMPC, DMPE, and DMPS, all of which have a net positive charge on their head group at a pH of 2.2, yielded a d-spacing of 44{acute over (Å)} (
FIG. 4A ). DMPG, a saturated lipid with a neutral charge at pH 2.2 yielded a d-spacing of 47{acute over (Å)} DMPC and DMPE generated very long range order with 4th order diffraction peaks in a ratio of 1:2:3:4. DMPG created two lamellar spacings. DMPS-silica assemblies do not create long-range order as observed in other saturated lipids. This is believed to be in part due to the carboxylic group in the headgroup of DMPS. - Lipid-silica assemblies made with unsaturated lipids DOPE and DOPC, both of which have a positive charge at pH 2.2, showed well defined lamellar structures with d-spacing corresponding to 48.4 {acute over (Å)} and 47.4 {acute over (Å)} with two orders of diffraction peaks as expected from unsaturated tails. No structure was obtained for lipid DOPA-silica assembly which has a negative charge at a pH 2.2.
- The failure of the neutrally charged DMPG to generate long range order and of the negatively charged DOPA to form lipid-silica assemblies indicates the importance of the head group charge in the formation of assemblies.
- Lipid DOPE and EggPC in chloroform (Avanti Polar Lipids (Alabaster, Ala.)) were combined in a 1:1 ratio and hydrated for one hour with the stock sol of Example I. Aliquots of the resulting mixture were then homogenized by vortexing for 5 minutes at room temperature and then either coated directly onto silicon wafers or subjected to sonication for 5 minutes in an ice bath using a VWR bath sonicator (power rating-9) (VWR International, West Chester, Pa.) before being coated at a speed of 3000 RPM for one minute onto silicon wafers which had previously been cleaned with a piranha solution of a 3:1 mixture of sulfuric acid and 30% hydrogen peroxide.
- The resulting films were characterized using X-ray diffraction and transmission electron microscopy. X-ray diffraction was performed using a Siemens D500 diffractometer (NY, N.Y.) using Ni filtered CuKα radiation with λ-1.5406{acute over (Å)} in θ−2θ) (2θ=0.8°-8.0° step-scan mode using a step size 0.02° for 3 seconds. Transmission electron microscopy was performed using a JEOL 2010 (Tokyo, Japan) with 200 kv accelerating voltage equipped with a Gatan slow scan CCD camera (Pleasanton, Calif.). The samples were prepared either by scratching the films from silicon substrates using a cutting blade or by using standard cross-section techniques.
- As can be seen in
FIG. 5 , two different lamellar assemblies were observed in the X-ray diffraction of the film made using the solution that was not subjected to sonication whereas only one lamellar assembly was visible in the X-ray diffraction of the film made using the solution that was subjected to subjected to sonication in an ice bath using a VWR bath sonicator (power rating-9) (West Chester, Pa.) for 1 hour with 1 minute rest every 15 minutes before being coated at a speed of 3000 RPM for one minute onto silicon wafers which had previously been cleaned with a piranha solution of a 3:1 mixture of sulfuric acid and 30% hydrogen peroxide. - 1.25 mg of EggPC from Avanti Polar Lipids (Alabaster, Ala.) was dissolved in 200 μl of deionized water and hydrated for 1 hour. A portion of the resulting solution was treated to sonication at 4° C. using a VWR bath sonicator (power rating-9) (VWR International, West Chester, Pa.) for 1 hour with a one minute interval after every 15 minutes of sonication. 200 μl of stock sol from Example I was then added to this liposomal solution. The remainder of the solution was not treated to sonication. Both the sonicated and unsonicated solutions were coated at a speed of 3000 RPM for one minute onto silicon wafers which had previously been cleaned with a piranha solution of a 3:1 mixture of sulfuric acid and 30% hydrogen peroxide.
- As can be seen in
FIG. 7A , multilamellar vesicles of approximately 50 nm were packed together in a uniform manner in the film created using the sonicated sample. FIG. 7B provides a comparison of the x-ray diffraction pattern of the sonicated (upper line) and unsonicated samples (lower line). - bR-containing purple membranes (lyophilized) composed primarily of phosphatidylglycerosulphate methyl ester and 3-HSO3-Galp-β1, 6-Manp-α-1,2-Glcp-α1, 1-sn-2,3-diphytanylglycerol (Munich innovative Biomaterials GmbH, Germany) were combined with dried DOPE (Avanti Polar Lipids (Alabaster, Ala.)) at a ratio of 1:100. The resulting powder was then hydrated for one hour with stock sol from Example I. The resulting mixture was then homogenized by vortexing for 5 minutes at room temperature. The homogenized mixture was then either coated onto silicon wafers as it was, or subjected to sonication for 5 minutes at room temperature using a VWR bath sonicator (power rating-9) (VWR International, West Chester, Pa.) before being coated onto silicon wafers. Both solutions were coated at a speed of 3000 RPM for one minute onto silicon wafers which had previously been cleaned with a piranha solution of a 3:1 mixture of sulfuric acid and 30% hydrogen peroxide.
- The resulting films were characterized using X-ray diffraction and transmission electron microscopy. X-ray diffraction was performed using a Siemens D500 diffractometer (NY, N.Y.) using Ni filtered CuKα radiation with λ-1.5406{acute over (Å)} in θ-2θ) (2θ=0.8°-8.0° step-scan mode using a step size 0.02° for 3 seconds. Transmission electron microscopy was performed using a JEOL 2010 (Tokyo, Japan) with 200 kv accelerating voltage equipped with a Gatan slow scan CCD camera (Pleasanton, Calif.). The samples were prepared either by scratching the films from silicon substrates using a cutting blade or by using standard cross-section techniques.
- As can be seen in
FIG. 8A , the TEM micrograph of a bR-DOPE-silica thin film without sonication shows the presence of multi-lamellar vesicle like structures. The x-ray diffraction pattern of the same film (FIG. 8C ) shows two distinct peaks of different d-spacing with one peak corresponding to a d-spacing of −46{acute over (Å)} and another peak corresponding to 53 {acute over (Å)}. Analysis of a film prepared with a solution treated to sonication reveals planar lamellar structures (8B) and x-ray diffraction revealed a single d-spacing of ˜46{acute over (Å)}. - The purple membrane is composed primarily of phosphatidylglycerosulphate methyl ester and 3-HSO3-Galp-β1, 6-Manp-α1,2-Glcp-α1,1-sn-2, 3-diphytanylglycerol which generally creates a high negative charge density on the membrane surfaces and can therefore inhibit the formation of ordered lamellar structures. However, despite this limitation, as seen in
FIG. 8 , the inclusion of purple membrane components with the DOPE formulation results in the formation of multi-lamellar vesicle like structures. - Gramicidin (Sigma Aldrich (St. Louis, Mo.)) was combined with dried DOPE (Avanti Polar Lipids (Alabaster, Ala.)) at a ratio of 1:10. The resulting powder was then hydrated for one hour with stock sol from Example I. The resulting mixture was then homogenized by vortexing for 5 minutes at room temperature. The homogenized mixture was then either coated onto silicon wafers as it was, or subjected to sonication for 5 minutes at room temperature using a VWR bath sonicator (power rating-9) (VWR International, West Chester, Pa.) before being coated onto silicon wafers. Both solutions were coated at a speed of 3000 RPM for one minute onto silicon wafers which had previously been cleaned with a piranha solution of a 3:1 mixture of sulfuric acid and 30% hydrogen peroxide.
- The resulting films were characterized using x-ray diffraction and transmission electron microscopy (TEM). X-ray diffraction was performed using a Siemens D500 diffractometer (NY, N.Y.) using Ni filtered CuKα radiation with λ-1.5406{acute over (Å)} in θ-2θ) (2θ=0.8°-8.0° step-scan mode using a step size 0.02° for 3 seconds. Transmission electron microscopy was performed using a JEOL 2010 (Tokyo, Japan) with 200 kv accelerating voltage equipped with a Gatan slow scan CCD camera (Pleasanton, Calif.). The samples were prepared either by scratching the films from silicon substrates using a cutting blade or by using standard cross-section techniques.
- As can be seen in
FIG. 9A-D , the x-ray diffraction pattern of the DOPE-silica thin films with and without gramicidin are similar. This similarity was further confirmed by TEM analysis which revealed the planar lamellar structure of these films. - Although the foregoing invention has been described in detail by way of example for purposes of clarity of understanding, it will be apparent to the artisan that certain changes and modifications may be practiced within the scope of the appended claims which are presented by way of illustration not limitation. In this context it will be understood that this invention is not limited to the particular formulations, process steps, and materials disclosed herein as such formulations, process steps, and materials may vary somewhat. It will also be understood that the terminology employed herein is used for the purpose of describing particular embodiments only, and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims and equivalents thereof. It is further noted that various publications and other reference information have been cited within the foregoing disclosure for economy of description. Each of these references are incorporated herein by reference in its entirety for all purposes. It is noted, however, that the various publications discussed herein are incorporated solely for their disclosure prior to the filing date of the present application, and the inventors reserve the right to antedate such disclosure by virtue of prior invention.
-
- Alouf, J. E. 2001. “Pore-forming bacterial protein toxins: an overview”. Pore-Forming Toxins 257:1-14.
- Alves, I. D.; Salgado, G. F. J.; Salamon, Z.; Brown, M. F.; Tollin, G.; and Hruby, V. J.; Biophysical Journal 2005, 88, 198.
- Asoh, H., K. Nishio, M. Nakao, A. Yokoo, T. Tamamura, and H. Masuda. 2001. “Fabrication of Ideally Ordered Anodic Porous Alumina with 63 nm Hole Periodicity Using Sulfuric Acid”. J Vac Sci Technol B 19:569-572.
- Baca, H. K.; Ph.D. Thesis, University of New Mexico, Albuquerque, N. Mex., 2005.
- Bayley, H., O. Braha, and L. Q. Gu. 2000. “Stochastic sensing with protein pores”. Advanced Materials 12:139-142.
- Bayley, H.; Braha, O.; Gu, L Q. Advanced Materials. 2000, 12, 139.
- Blank, M. 1995. “Electric and Magnetic-Field Signal-Transduction in the Membrane Na+/K+-Adenosine-Triphosphatase”. Advances Chem 250:339-248.
- Bore, M. T.; Rathod, S. B.; Ward, T. L.; Datye, A. K.; Langmuir 2003, 19, 256. [38]
- Knight, C. G.; Liposomes from physical structure to therapeutic applications. ElseiverlNorth-Holland Biomedical Press. 1981, Ch. 8.
- Brinker, C. J., and G. W. Scherrer. 1900. Sol-Gel Science. Academic Press.
- Brinker, C. J., Y. Lu, A. Sellinger, and H. Fan. 1999. “Evaporation-Induced Self-Assembly: Nanostructures Made Easy”. Adv. Mater. 11:579-585.
- Buranda, T., J. Huang, G. V. Rama Rao, L. K. Ista, R. S. Larson, T. L. Ward, L. A. Sklar, and G. P. Lopez. 2002. “Biomimetic Molecular Assemblies on Glass and Mesoporous Silica Microbeads for Biotechnological Applications”. Langmuir In press.
- Cartailler, J-P; Luecke, H.; Annu. Rev. Biophys. Biomol. Struct. 2003, 326, 1317. [1,8] Lanyi, J. K.; Pohorille, A.;
Trends Biotechnol 2001, 19, 140. - Caruso, R. A.; Antonietti, M.; Chemistry of Materials. 2001, 13, 3272.
- Chilkoti, A., G. H. Chen, P. S. Stayton, and A. S. Hoffman. 1994. “Site-Specific Conjugation of a Temperature-Sensitive Polymer to a Genetically-Engineered Protein” Bioconjugate Chem 5:504-507.
- Coleman, N. R. B.; Attard, G. S.; Microporous and Mesoporous Materials. 2001, 44, 73
- Cornell, B. A., V. L. B. Braach-Maksvytis, L. G. King, P. D. J. Osman, B. Raguse, L. Wieczorek, and R. J. Pace. 1991. “A Biosensor that Uses Ion-Channel Switches”. Nature 387:580-583.
- Doshi, D. A., N. K. Huesing, H. Y. Fan, K. S. Potter, B. G. Potter, A. J. Hurd, and C. J.
- Brinker. 2000. “Optically, Defined Multifunctional Patterning of Photosensitive Thin-Film Silica Mesophases”. Science 290: 107-111.
- Du, P., and I. Alkorta. 1994. “Sequence Divergence Analysis for the Prediction of 7-Helix Membrane-Protein Structures. 1. Comparison with Bacteriorhodopsin”. Protein Eng 7:1221-1229.
- Edman, K., P. Nollert, A. Royant, H. Belrhali, E. Pebay-Peyroula, J. Hajdu, R. Neutze, and E. M. Landau. 1999. “High-Resolution X-Ray Structure of an Early Intermediate in the Bacteriorhodopsin Photocycle”. Nature 401:822-826.
- Fernandez-Lopez, S., H. S. Kim, E. C. Choi, M. Delgado, J. R. Granja, A. Khasanov, K. Kraehenbuehl, G. Long, D. A. Weingberger, K. M. Wilcoxen, and M. R. Ghadiri. 2001. “Antibacterial agents based on the cyclic D,L-alpha-peptide architecture”. Nature 414:329-329.
- Garavito, R. M.; Ferguson-Miller, S.; J. Biol. Chem. 2001, 276, 32403
- Garza, A. G., H. L. W., R. A. Stoebner, and M. D. Manson. 1995. “Motility Protein Interactions in the Bacterial Flagellar Motor”. Proc Natl Acad Sci USA 92:1970-1974.
- Harris, R. A., and A. M. Allan. 1985. “Functional Coupling of Gamma-Aminobutyric Acid Receptors to Chloride Channels in Brain Membranes”. Science 228:1108-1110.
- Haupts, U., J. Tittor, and D. Oesterhelt. 1999. “Closing in on Bacteriorhodopsin: Progress in Understanding the Molecule”. Annu Rev Biophys Biomed Struct 28:367-399.
- He, J. A., L. Samuelson, L. Li, J. Kumar, and S. K. Tripathy. 1999. “Bacteriorhodopsin Thin Film Assemblies: Immobilization, Properties, and Applications”. Adv Mater 11:435-446.
- He, J. A.; Samuelson, L.; Li, L.; Kumar, J.; Tripathy, S. K.; Advanced Materials 1999, 11, 435.
- Hoffman, A. S., P. S. Stayton, T. Shimoboji, G. H. Chen, Z. L. Ding, A. Chilkoti, C. Long, M. Miura, J. P. Chen, T. Park, N. Monji, C. A. Cole, J. M. Harris, and K. Nakamae. 1997. “Conjugates of Stimuli-Responsive Polymers and Biomolecules: Random and Site-Specific Conjugates of Temperature-Sensitive Polymers and Proteins”. Macromolec Symp 118:553-563.
- Hoffman, A. S., P. S. Stayton, V. Bulmus, G. H. Chen, J. P. Chen, C. Cheung, A. Chilkoti, Z. L. Ding, L. C. Dong, R. Fong, C. A. Lackey, C. J. Long, M. Miura, J. E. Morris, N. Murthy, Y. Nabeshima, T. G. Park, 0. W. Press, T. Shimoboji, S. Shoemaker, H. J. Yang, N. Monji, R. C. Nowinski, C. A. Cole, J. H. Priest, J. M. Harris, K. Nakamae, T. Nishinom, and T. Miyata. 2000. “Really Smart Bioconjugates of Smart Polymers and Receptor Proteins”. J Biomed Mater Res 52:140-144.
- Ishibashi, K., M. Kuwahara, and S. Sasaki. 2000. “Molecular Biology of Aquaporins”. Rev Physiol Bioch P 14:1-32.
- Ishibashi, K.; Kuwahara, M.; Sasaki, S.; Rev.
2000, 14, 1.Physiol Bioch P - Ista, L. K., S. Mendez, V. H. Perez-Luna, and Lopez GP. 2001. “Synthesis of Poly(NIsopropylacrylamide) on Initiator-Modified Self-Assembled Monolayers”. Langmuir 17:2552-2555.
- Ista, L. K., V. H. Perez-Luna, and G. P. Lopez. 1999. “Surface-Grafted, Environmentally Sensitive Polymers for Biofilm Release”. Appl. Environ. Microbiol. 65:1603-1609.
- J. N. Israelachivili, J. N.; Intermolecular & Surface forces by Second Edition. 1992. [28]
- Karkamkar, A. J.; Kim, S. S.; Mahanti, S. D.; Pinnavaia, T. J.; Advanced Functional Materials, 2004, 14, 507-512
- Kleinschrnidt, J. H.; Tamm, L. K.; Biophysical Journal 2002, 83 994-1003
- Konig, J., A. T. Nies, Y. H. Cui, I. Leier, and D. Keppler. 1999. “Conjugate Export Pumps of the Multidrug Resistance Protein (MRP) Family: Localization, Substrate Specificity, and MRP2-Mediated Drug Resistance”. BBA Biomembranes 1461:377-394.
- Ko'ta, Z.; Pa'Li, T.; and Marsh D.; Biophysical Journal 2004, 86, 1521-1531
- Kuramoto, N., and Y. Shishido. 1998. “Property of Thermo-Sensitive and Redox Active Poly(N-Cyclopropylacrylamide-co-vinylferrocene) and Poly(N-Isopropylacrylamidecovinylferrocene)”. Polymer 39:669-673.
- Lanyi, J. K., and A. Pohorille. 2001. “Proton Pumps: Mechanism of Action and Applications”. Trends Biotechnol 19: 140-144.
- Lu, Y.; Ganguli, R.; Drewien, C. A.; Anderson, M. T.; Brinker, C. J.; Gong, W.; Guo, Y.; Soyez, H.; Dunn, B.; Huang, M. H.; Zink, J. I.; Nature, 1997, 389, 364.
- Lu, Y. F., Y. Yang, A. Sellinger, J. M. Lu, J. M. Huang, H. Y. Fan, R. Haddad, G. P. Lopez, A. R. Burns, D. Y. Sasaki, J. Shelnutt, and C. J. Brinker. 2001. “Self-Assembly of Mesoscopically Ordered Chromatic Polydiacetylene/Silica Nanocomposites”. Nature 411:913-917.
- Lu, Y. F.; Yang, Y.; Sellinger, A.; Lu, J. M.; Huang, J. M.; Fan, H. Y.; Haddad, R.; Lopez, G. P.; Burns, A. R.; Sasaki, D.Y.; Shelnutt, J.; Brinker, C. J. Nature 2001, 411, 913.
- Lu, Y. F., H.Y. Fan, N. Doke, D. A. Loy, R. A. Assink, D. A. LaVan, and C. J. Brinker. 2000. “Evaporation-Induced Self-Assembly of Hybrid Bridged Silsesquioxane Film and Particulate Mesophases with Integral Organic Functionality”. Journal of The American Chemical Society 122:5258-5261.
- Luecke, H., B. Schobert, H. T. Richter, J. P. Cartailler, and J. K. Lanyi. 1999. “Structural Changes inn Bacteriorhodopsin During Ion Transport at 2 Angstrom Resolution”. Science 286:255-260.
- Luo, T. J. M.; Soong, R.; Lan, E.; Dunn, B.; and Montemagno, C.;
Nature Materials 2005, 5, 220. - Marsh, D.; CRC Handbook of Lipid Bilayers 1990.
- Martinez-Landeira, P.; Ruso, J. M.; Prieto, G.; Sarmiento; F.; Journal of Chemica and Engineering Data. 2002, 47, 1017-1021
- McCaughey, B.; Hampsey, J. E.; Wang, D.; Lu; Y.; Encyclopedia of Nanoscience and Nanotechnology, 2004, 9, 529-559.
- Meyer, D. E., K. Trabbic-Carlson, and A. Chilkoti. 2001. “Protein Purification by Fusion with an Environmentally Responsive Elastin-Like Polypeptide: Effect of Polypeptide Length on the Purification of Thioredoxin”. Bzotechnol Progr 17:720-728.
- Meyer, D., and A. Chilkoti. 1999. “Purification of Recombinant Proteins by Fusion with Thermally-Responsive Polypeptides”. Nut Biotechnol 17:1112-1115.
- Moeck, G. S., and J. W. Coulton. 1998. “TonB-Dependent Iron Acquisition: Mechanisms of Siderophore-Mediated Active Transport”. Mol Microbiol 28:675-681.
- Moeck, G. S.; and Coulton, J. W. J. Mol. Microbial. 1998, 28, 675.
- Nakane, J., M. Akeson, and A. Marziali. 2002. “Evaluation of nanopores as candidates for electronic analyte detection”. Electrophoresis 23:2592-2601.
- Nath, N., and A. Chilkoti. 2001. “Interfacial Phase Transition of an Environmentally Responsive Elastin Biopolymer Adsorbed on Functionalized Gold Nanoparticles Studied by Colloidal Surface Plasmon Resonance”. JArner Chem Soc 123:8197-8202.
- Nelson, D. L.; M. M. Cox, M. M. Lehninger Principles of Biochemistry, 4th Edition. W. H. Freeman and Company, 2004; Ch. 11.
- Nicolini, C. Biosensors and Bioelectronics. 1995, 10, 105.
- Nicolini, C., V. Erokhin, S. Paddeu, and M. Sartore. 1998. “Towards a Light Addressable Transducer Bacteriorhodopsin-Based”. Nanotechnology 9:222-227.
- Nicolini, C.; Erokhin, V.; Paddeu, S.; Sartore, M.; Nanotechnology 1998, 9, 223. [24]
- Finkelstein, A.; Andersen, O, S.; J Membr Biol. 1981, 59, 155.
- Ottenbacher, D.; Kindervater, R.; Gimmel, P.; Klee, B.; Jahnig, F.; Gopel, W. Sensors and Actuators B-Chemical. 1992, 6, 192.
- Parsons, S. M. 2000. “Transport Mechanisms in Acetylcholine And Monoamine Storage”. FASEB J 14:2423-2434.
- Parsons, S. M.; FASEB J. 2000, 14, 2423.
- Philippot R. J.; Schuber, F. Liposomes as tools in basic research and industry. CRC Press 1995, Ch. 5.
- Rama Rao, G. V., and G. P. Lopez. 2000. “Encapsulation of Poly(N-Isopropyl Acrylamide) in Silica: A Stimuli-Responsive Porous Hybrid Material that Incorporates Molecular Nano-Valves”. Advanced Materials 12:1692-1 695.
- Rama Rao, G. V., G. P. Lopez, J. Bravo, H. Pham, A. K. Datye, H. Xu, and T. L. Ward. 2002. “Monodisperse Mesoporous Silica Microspheres Formed by Evaporation-Induced Self-Assembly of Surfactant Templates in Aerosols”. Advanced Materials 14:1301-1304.
- Rama Rao, G. V., S. Balarnurugan, D. E. Meyer, A. Chilkoti, and G. P. Lopez. 2002. “Hybrid bio-inorganic smart membranes that incorporate protein-based molecular switches”. Langmuir 18:1819-1824.
- Rama Rao, G. V.; Lopez, G. P.; Bravo, J.; Pham, H.; Datye, A. K.; Xu, H.; Ward, T. L. Advanced materials. 2002, 14, 1301.
- Royant, A., K. Edman, T. Ursby, E. Pebay-Peyroula, E. M. Landau, and R. Neutze. 2000. “Helix Deformation Is Coupled to Vectorial Proton Transport in the Photocycle of Bacteriorhodopsin”. Nature 406:645-648.
- Sabine, J. R.; Cholesterol. 1977
Chapter 2, 5-26. - Stayton, P. S., T. Shimoboji, C. Long, A. Chilkoti, G. H. Chen, J. M. Harris, and A. S. Hoffman. 1995. “Control of Protein-Ligand Recognition Using a Stimuli-Responsive Polymer”. Nature 378:472-474.
- Stoeckenius, W. 1999. “Bacterial Rhodopsins: Evolution of a Mechanistic Model for the Ion Pumps”. Protein Sci 8:447-459.
- Stryer, J; Biochemistry, 4th Edition, W. H. Freeman and Company, 1995, Ch. 12.
- Su, L.Y.; Hawkridge, F. M.; Rohten, M. C. Chemistry and Biodiversity. 2004, 1, 1281.
- Urry, D. W. 1997. “Physical Chemistry of Biological Free Energy Transduction as Demonstrated by Protein-Based Polymers”. J. Phys. Chem. B 101:11007-11028.
- Yamaguchi, S.; Hong, T.; Waring, A.; Lehrer, R. I.; Hong, M.;
Biochemistry 2002, 4, 9852. - Yamanaka, S. A.; Charych, D. H.; Loy, D. A.; and Sasaki, D. Y.;
Langmuir 1997, 13, 5049. - Yan, J. C., L. M. Tender, P. D. Hampton, and G. P. Lopez. 2001. “Direct Electrochemical Transduction of Biorecognition at Viologen-Containing Monolayer Surfaces”. JPhys Chem B 105:8905-8910.
- Yan, J. C., V. R. Goparaju, G. P. Lopez, and P. Atanasov. Unpublished data.
- Yeagle, P.; The Structure of Biological Membranes. 1992.
Chapter 1 to 4, 3-210 - Cevc, G.; Watts, A.; Marsh, D.;
Biochemistry 1981, 20, 4955-4965 - Hayward, R. C., D. A. Saville, and I. A. Aksay. 2000. “Electrophoretic Assembly of Colloidal Crystals with Optically Tunable Micropatterns”. Nature 404:56-59.
- Delamarche, E., G. Sundarababu, H. Biebuyck, B. Michel, C. Gerber; H. Sigrist, H. Wolf, H. Ringsdorf, N. Xanthopoulos, and H. J. Mathieu. 1996. “Immobilization of Antibodies on a Photoactive Self-Assembled Monolayer on Gold”. Langmuir 12:1997-2006.
- Yen, H. R. H., J. D. Andrade, and J. Kopecek. “Optically Controlled Ligand Delivery 0.3. Photocleavage of 2-Nitrobenzyl Bonds at Solid Liquid Interfaces”. Polymer 33:1783-1767 (1992).
Claims (18)
1. An artificial hybrid lipid-polymer membrane comprising a biomolecular complex, wherein the membrane exhibits substantially constant d-spacing.
2. The hybrid lipid-polymer membrane of claim 1 wherein the d-spacing is between 35 to 48 {acute over (Å)}.
3. The hybrid lipid-polymer membrane of claim 1 wherein the structure of the membrane is a planar lamellar structure.
4. The hybrid lipid-polymer membrane of claim 1 wherein the polymer is inorganic.
5. The hybrid lipid-polymer membrane of claim 1 wherein the polymer is organic.
6. The hybrid lipid-polymer membrane of claim 1 wherein the polymer is an inorganic-organic hybrid.
7. The hybrid lipid-polymer membrane of claim 4 wherein the inorganic polymer is silica.
8. The hybrid lipid-silica membrane of claim 7 wherein the silica is formed from tetramethylorthosilicate, tetraethylortho silicate, aminopropyltrimethyoxysilane, hydroxymethyltriethoxysilane, or methacryloxypropyl trimethoxysilane.
9. The hybrid lipid-polymer membrane of claim 5 wherein the organic polymer is formed from poly (vinyl alcohol), poly (vinyl pyrrolidone), poly (ethylene oxide), hydroxy-propyl cellulose, dextran, agarose, sucrose, glucose and trehalose; poly (acrylic acid), poly (sodium styrene sulphonate), poly acrylamide (PAM), alignate, chitosan-EDTA, carbomer, pectins, DNA, poly(diallyldimethylammonium chloride), chitosin, and poly-lysinehydroxyethyl methacrylate.
10. The hybrid lipid-polymer membrane of 1, wherein the lipid is 1,2-dimyristoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-pho sphoethanolamine, 1,2-dimyristo yl-sn-glycero-3-[phospho-rac-(1-glycerol)] (S odium Salt), 1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine (14:0 Lyso PC), 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1-oleoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, L-α-phosphatidylcholine or 1,1′,2,2′-tetramyristoyl cardiolipin.
11. The hybrid lipid-polymer membrane of claim 1 wherein the membrane is supported by a solid support.
12. The hybrid lipid-polymer membrane of claim 1 wherein the solid support is silicon wafer, silane-silicon, self-assembled monolayer-gold, SnO2, polymer coated substrate, gold, or porous Alumina.
13. The hybrid lipid-polymer membrane of claim 1 wherein the solid support is macroporous.
14. The hybrid lipid-polymer membrane of claim 1 wherein the solid support is microporous.
15. The hybrid lipid-polymer membrane of claim 1 wherein the biomolecular complex is a protein.
16. The hybrid lipid-polymer membrane of claim 1 wherein the biomolecular complex is a peptide.
17. The hybrid lipid-polymer membrane of claim 1 wherein the biomolecular complex is selected from the group consisting of a g couple protein receptor, an ion channel, a ligand gated channel, a voltage gated channel, a light gated channel, or an active transport system.
18. The hybrid lipid-polymer membrane of claim 1 wherein the biomolecular complex is selected from the group consisting of porins, alpha-hemolysin, or a toxin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/232,647 US20120058327A1 (en) | 2006-03-24 | 2011-09-14 | Robust Hybrid Thin Films that Incorporate Lamellar Phospholipid Bilayer Assemblies and Transmembrane Proteins |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78569906P | 2006-03-24 | 2006-03-24 | |
| US78612006P | 2006-03-27 | 2006-03-27 | |
| US11/690,922 US8114464B2 (en) | 2006-03-24 | 2007-03-26 | Hybrid thin films that incorporate lamellar phospholipid layer assemblies and transmembrane proteins |
| US13/232,647 US20120058327A1 (en) | 2006-03-24 | 2011-09-14 | Robust Hybrid Thin Films that Incorporate Lamellar Phospholipid Bilayer Assemblies and Transmembrane Proteins |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/690,922 Division US8114464B2 (en) | 2006-03-24 | 2007-03-26 | Hybrid thin films that incorporate lamellar phospholipid layer assemblies and transmembrane proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20120058327A1 true US20120058327A1 (en) | 2012-03-08 |
Family
ID=38712327
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/690,922 Active 2030-07-08 US8114464B2 (en) | 2006-03-24 | 2007-03-26 | Hybrid thin films that incorporate lamellar phospholipid layer assemblies and transmembrane proteins |
| US13/232,647 Abandoned US20120058327A1 (en) | 2006-03-24 | 2011-09-14 | Robust Hybrid Thin Films that Incorporate Lamellar Phospholipid Bilayer Assemblies and Transmembrane Proteins |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/690,922 Active 2030-07-08 US8114464B2 (en) | 2006-03-24 | 2007-03-26 | Hybrid thin films that incorporate lamellar phospholipid layer assemblies and transmembrane proteins |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US8114464B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106963980A (en) * | 2017-04-17 | 2017-07-21 | 华南理工大学 | A kind of preparation method of chitosan silicon dioxide nano-hybrid material and application |
| US9827529B2 (en) * | 2011-08-15 | 2017-11-28 | E I Du Pont De Nemours And Company | Breathable product for protective mass transportation and cold chain applications |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9719985B2 (en) * | 2009-08-03 | 2017-08-01 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of detection and related detection device |
| US12384699B2 (en) | 2010-05-21 | 2025-08-12 | Crosstek Holding Company Llc | Self-assembled surfactant structures |
| US10259723B2 (en) | 2010-05-21 | 2019-04-16 | Znano Llc | Self-assembled surfactant structures |
| EP2571607A4 (en) * | 2010-05-21 | 2016-12-21 | Adrian Brozell | SURFACE ASSISTING SURFACE STRUCTURES |
| DE102011080888A1 (en) | 2011-08-12 | 2013-02-14 | Technische Universität München | Process for the preparation of poly (hydroxymethyl) -functional siloxanes and silica gels |
| CN110507632A (en) * | 2019-08-19 | 2019-11-29 | 天津大学 | A preparation method of composite membrane wrapped mesoporous silica nanoparticles |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6375787B1 (en) * | 1993-04-23 | 2002-04-23 | Schneider (Europe) Ag | Methods for applying a covering layer to a stent |
| US20040093066A1 (en) * | 2002-09-26 | 2004-05-13 | Durcan Jonathan P. | Balloon expandable stent |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989587A (en) * | 1992-10-23 | 1999-11-23 | National Research Council Of Canada | Formation of stable liposomes from lipid extracts of archaeobacteria (archaeu) |
| US6048546A (en) * | 1997-07-31 | 2000-04-11 | Sandia Corporation | Immobilized lipid-bilayer materials |
| US7045367B2 (en) * | 2001-03-23 | 2006-05-16 | Michigan Molecular Institute | Nano-scaled dendrimer-based colorimetric biosensors |
-
2007
- 2007-03-26 US US11/690,922 patent/US8114464B2/en active Active
-
2011
- 2011-09-14 US US13/232,647 patent/US20120058327A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6375787B1 (en) * | 1993-04-23 | 2002-04-23 | Schneider (Europe) Ag | Methods for applying a covering layer to a stent |
| US20040093066A1 (en) * | 2002-09-26 | 2004-05-13 | Durcan Jonathan P. | Balloon expandable stent |
Non-Patent Citations (2)
| Title |
|---|
| Kortesuo, Sol-Gel Derived Silica Gel Monoliths and Micropartilces as Carrier in Controlled Drug Delivery in Tissue Administration, University of Helsinki, 2001, pp. 1-48 * |
| Warrinet et al., Lamellar Biogels: Fluid-Membrane-Based Hydrogels Containing Polymer Lipids, Science, 02-1996, Vol. 271, pp. 969-972 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9827529B2 (en) * | 2011-08-15 | 2017-11-28 | E I Du Pont De Nemours And Company | Breathable product for protective mass transportation and cold chain applications |
| CN106963980A (en) * | 2017-04-17 | 2017-07-21 | 华南理工大学 | A kind of preparation method of chitosan silicon dioxide nano-hybrid material and application |
Also Published As
| Publication number | Publication date |
|---|---|
| US20070269662A1 (en) | 2007-11-22 |
| US8114464B2 (en) | 2012-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120058327A1 (en) | Robust Hybrid Thin Films that Incorporate Lamellar Phospholipid Bilayer Assemblies and Transmembrane Proteins | |
| Jackman et al. | Self-assembly formation of lipid bilayer coatings on bare aluminum oxide: overcoming the force of interfacial water | |
| US8940173B2 (en) | Membranes with functionalized carbon nanotube pores for selective transport | |
| JP6031660B2 (en) | Self-assembled surfactant structure | |
| Cortez et al. | Highly-organized stacked multilayers via layer-by-layer assembly of lipid-like surfactants and polyelectrolytes. Stratified supramolecular structures for (bio) electrochemical nanoarchitectonics | |
| JP6028533B2 (en) | Method for producing selective permeable membrane | |
| Lee et al. | Two-dimensional designer nanochannels for controllable ion transport in graphene oxide nanomembranes with tunable sheet dimensions | |
| Puiggalí-Jou et al. | Biomimetic hybrid membranes: incorporation of transport proteins/peptides into polymer supports | |
| Schuster et al. | S-layer stabilized lipid membranes | |
| Diamanti et al. | Gramicidin ion channels in a lipid bilayer supported on polyelectrolyte multilayer films: an electrochemical impedance study | |
| Ruiz-Rincón et al. | Reversible Monolayer–Bilayer Transition in Supported Phospholipid LB Films under the Presence of Water: Morphological and Nanomechanical Behavior | |
| Achalkumar et al. | Cholesterol-based anchors and tethers for phospholipid bilayers and for model biological membranes | |
| Guo et al. | Three-phase coexistence in binary charged lipid membranes in a hypotonic solution | |
| Prieto et al. | Electrochemical characterization of a mixed lipid monolayer supported on Au (111) electrodes with implications for doxorubicin delivery | |
| Seimei et al. | Effect of polyelectrolyte structure on formation of supported lipid bilayers on polyelectrolyte multilayers prepared using the layer-by-layer method | |
| Paul et al. | Interaction of a Phospholipid and a Coagulating Protein: Potential Candidate for Bioelectronic Applications | |
| Gopal et al. | Composite phospholipid− calcium carbonate microparticles: Influence of anionic phospholipids on the crystallization of calcium carbonate | |
| Gromelski et al. | The formation of lipid bilayers on surfaces | |
| Bovin et al. | Oligoglycines: Materials with unlimited potential for nanotechnologies | |
| Damiati | Can we rebuild the Cell Membrane? | |
| Miyashita et al. | Formation of supported lipid bilayers on porous polymeric substrates induced by hydrophobic interaction | |
| De Moraes et al. | Supramolecular systems | |
| Gupta et al. | Robust hybrid thin films that incorporate lamellar phospholipid bilayer assemblies and transmembrane proteins | |
| Wlodek et al. | Formation and characterization of (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)/(1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-l-serine) supported lipid bilayers on polyelectrolyte multilayer films | |
| Tsukanov et al. | A Review of computer simulation studies of cell membrane interaction with neutral and charged nano-objects. Quasi-zero-dimensional nanoparticles, drugs and fullerenes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |